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Summary 
Ubiquitination is an essential posttranslational protein modification (PTM) that regulates 
widespread intracellular processes in eukaryotic cells. Ubiquitin (Ub) can be assembled into 
polymeric chains through its seven internal lysine residues and the N-terminus. Considering the 
high number of possible combinations, it becomes evident that the molecular machinery 
assembling this "Ubiquitin Code" needs to be tightly regulated. Often E2 ubiquitin-conjugating 
enzymes play a key role in defining the shape of a ubiquitin signal. However, factors that guide 
their activity remain poorly understood. In this study, I investigated the molecular 
underpinnings of Ub chain assembly by the E2 enzymes Ubc1 and Ubc7 through in vitro 
reconstitution of ubiquitination activity, biochemical assays, structural investigation and cell 
biological experiments. This study shows that associated ubiquitin bindings domains (UBDs) 
substantially contribute to the assembly of particular Ub chains by both E2 enzymes. 
Uniquely among the eleven E2 enzymes of S. cerevisiae Ubc1 contains a ubiquitin binding 
UBA domain. Ubc1 exclusively modifies lysine 48 (K48) in Ub and has been implicated in 
protein quality control and cell cycle progression. However, the function of its UBA domain 
remained elusive. I identified Ubc1 to preferentially target specific Ub molecules in K63-linked 
polyubiquitin via its UBA domain. This activity results in the assembly of K48/K63 branched 
Ub chains. Based on existing structural information and my own X-ray crystallographic 
experiments, I propose a structure for the transition state of branched chain assembly by Ubc1. 
Although homotypic ubiquitin chains have been thoroughly studied, little is known about the 
prevalence and function of mixed or branched chains. My findings provide a basis for their 
study. 
Ubc7 has previously been shown to be activated by its co-factor Cue1 to assemble Ub chains 
linked through lysine 48 (K48) in the context of endoplasmic reticulum associated protein 
degradation (ERAD). I studied Ubc7 and Cue1 in collaboration with Dr. Maximilian von 
Delbrück (AG Sommer - MDC, Berlin) and Dr. Andreas Kniss (AG Dötsch - Goethe University, 
Frankfurt). We identified the ubiquitin binding CUE domain in Cue1 to play a key role in 
aligning Ubc7 with the distal tip of a K48-linked Ub chain for rapid chain elongation. 
Furthermore, we showed how binding of Ub by the CUE domain is well adapted towards the 
chain elongation process and how its disruption impairs degradation of the ERAD substrate 
Ubc6.   
VIII 
Zusammenfassung 
Ubiquitinierung ist eine essentielle posttranslationale Proteinmodifikation (PTM), die 
vielfältige Prozesse in eukaryotischen Zellen reguliert. Ubiquitin (Ub) wird sowohl durch 
sieben interne Lysin-Reste als auch durch den Amino-Terminus zu polymeren Ketten 
zusammengesetzt. Aus den zahlreichen Kombinationsmöglichkeiten ergeben sich komplexe 
intrazelluläre Signale, die durch spezialisierte Enzyme selektiv aufgebaut werden. Häufig sind 
hierbei E2-Ubiquitin-konjugierende Enzyme von entscheidender Bedeutung. Über Faktoren, 
die ihre Aktivität regulieren, war bisher jedoch wenig bekannt. Im Rahmen meines 
Promotionsstudiums habe ich die molekularen Grundlagen der Ub-Kettensynthese durch die 
E2-Enzyme Ubc1 und Ubc7 untersucht. Hierzu habe ich in vitro Ubiquitinierungs-Reaktionen, 
biochemische und strukturelle Untersuchungen sowie zellbiologische Experimente 
durchgeführt. Hierbei wurde deutlich, dass Ubiquitin-Binde-Domänen (UBDs), welche mit den 
E2-Enzymen assoziiert sind, wesentlich zum effizienten und spezifischen Aufbau von Ub-
Ketten beitragen. 
Als einziges unter elf E2-Enzymen in S. cerevisiae enthält Ubc1 eine Ubiquitin-bindende 
UBA-Domäne. Ubc1 modifiziert ausschließlich Lysin 48 (K48) in Ub und wurde mit 
Proteinqualitätskontrolle sowie der Regulation des Zellzyklus in Verbindung gebracht. Die 
Funktion der UBA-Domäne blieb hierbei jedoch unklar. Die Ergebnisse meiner Studie zeigen, 
dass Ubc1 mithilfe seiner UBA-Domäne vorzugsweise mit bestimmten Ub-Molekülen in K63-
verknüpftem Polyubiquitin interagiert. Diese Aktivität führt zur Assemblierung von K48/K63 
verzweigten Ub-Ketten. Basierend auf vorhandenen Strukturinformationen und meinen eigenen 
röntgenkristallographischen Untersuchungen habe ich eine Modellstruktur für den 
Übergangszustand dieser Reaktion erarbeitet. Homotypische Ubiquitinketten sind Gegenstand 
zahlreicher Studien, während über die Prävalenz und Funktion von gemischten oder 
verzweigten Ub-Ketten wenig bekannt ist. Für letztere bilden meine Ergebnisse eine 
wesentliche Untersuchungsgrundlage. 
Ubc7 assembliert mit seinem Kofaktor Cue1 Ub-Ketten, die K48-verknüpft sind, für den 
Endoplasmatisches-Retikulum-assoziierten Proteinabbau (ERAD). Im Rahmen eines 
kollaborativen Projektes, konnten wir zeigen, dass die Ubiquitin-bindende CUE-Domäne in 
Cue1 eine Schlüsselrolle bei der Ausrichtung von Ubc7 spielt. Hierbei wird das E2-Enzym in 
der Nähe der distalen Spitze einer K48-verknüpften Ub-Kette positioniert, um eine schnelle 
Kettenverlängerung zu ermöglichen. Darüber hinaus konnten wir zeigen, wie die Bindung der 
CUE-Domäne an Ub besonders an den Kettenverlängungsprozess angepasst ist, und dass eine 
Beeinträchtigung dieser Bindung den Abbau des ERAD-Substrats Ubc6 inhibiert.  
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1. Introduction 
1.1 The Ubiquitin Code 
1.1.1 Ubiquitination 
All living cells must react to changes in their environment to assure survival. This includes cells 
inside the protective surroundings of multicellular organisms. Among other external and 
internal factors they must rapidly adapt to changing chemical and electric stimuli, nutrient 
availability and temperature. The eukaryotic cell is capable of responding quickly to such 
changes by means of different molecular tools. Post-translational protein modifications (PTMs) 
like phosphorylation, acetylation and ubiquitination are pivotal to this ability. Ubiquitin-
mediated protein degradation was a discovery in the early 1980s for which Aaron Ciechanover, 
Avram Hershko and Irwin Rose were jointly awarded the Nobel Prize in Chemistry in 2004.3 
Since its discovery, the highly stable 76-amino acid protein ubiquitin (Ub) was found to not 
only affect the half-life of its client proteins, but also their cellular localisation, their interactome 
and their activity.4,5 Moreover, Ub itself is also a target of PTMs including ubiquitination. Thus, 
unlike many other modifications, Ub does not only encode a binary signal, which occurs in 
either of two states, but instead can harbour complex information. This so-called Ubiquitin 
Code was found to regulate widespread cellular functions in all kinds of eukaryotic tissue and 
organisms from yeast to human. The pleiotropic effects of ubiquitination are implicated in 
human development and disease in numerous ways.6,7 Therefore, understanding how the 
Ubiquitin Code is generated and decoded by downstream acting factors is a fundamental and 
far-reaching question.  
In the first part of this introduction, I describe general properties and structural features of Ub, 
which are the basis for the complexity of the Ubiquitin Code. In the second part, I introduce 
enzymes which are central in the generation of the Ubiquitin Code. The factors which guide the 
activity of these proteins remain largely elusive and are a major focus of this study. Ultimately, 
I formulate a simplified nomenclature to discuss complex Ub signals.  
Ub is transferred to target proteins by the combined action of ubiquitin-activating enzymes (E1), 
ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3).4 As the result of this enzymatic 
cascade, a Ub monomer is covalently attached via its C-terminus to a target protein typically 
through the ε-amino group of a lysine residue (Figure 1). Eukaryotic cells employ a large 
number of proteins to ascertain assembly of Ub signals within particular cellular contexts on 
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Figure 1: The Ubiquitin Code. (A) Ubiquitin is attached to a protein substrate through enzymatically catalysed 
formation of an isopeptide bond between the C-terminal carboxy group of ubiquitin (Ub) and an amino group of a 
target lysine. Ub may serve as a new binding site for effector proteins or block existing binding sites for interaction 
partners. (B) The three-dimensional structure of Ub (PDB: 2K39). Ub harbours seven lysine residues and the N-
terminal M1 which can also be targeted by ubiquitination resulting in the assembly of polymeric chains. Amino 
groups are highlighted in blue and the C-terminal carboxy group in red. (C) Differently linked Ub chains lead to 
different biological outcomes. Ub chains linked through K48 (K48 chains) are typically associated with 
proteasomal degradation of a substrate. In contrast, K63 chains facilitate the recruitment of a range of non-
proteasomal effector proteins. (D) Different linkage types can be combined into one signal yielding mixed and 
branched Ub chains. 
defined substrates. The human genome encodes for an estimated total of 600-1000 E3 enzymes, 
approximately forty E2 enzymes and two E1 enzymes, which are involved in the transfer of Ub 
and ubiquitin-like proteins.8 In some cases, enzymes have redundant functions and overlapping 
substrate pools which can complicate their study. This makes the yeast S. Cerevisiae an 
attractive model organism for the study of the Ubiquitin Code. Its genome encodes for 
approximately 60-100 E3 enzymes and 13 E2 enzymes.9 
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Signal termination plays an important role for ubiquitination as for any other signalling cascade. 
This is achieved by enzymes known as deubiquitinating enzymes (DUBs). These proteases 
catalyse a proteolytic reaction between the carboxy group of the C-terminus in Ub and its 
attachment site.10 Different DUBs selectively cleave specific Ub signals depending on their 
topology. DUBs ensure maintenance of a steady pool of free Ub, but also mediate acute 
signalling events by removing binding sites for downstream effectors in a tightly controlled 
manner. In mammalian cells, approximately 100 DUBs have been identified which can be 
subdivided into six families.11,12,13 
After the discovery of Ub more proteins emerged, which share its characteristic three-
dimensional β-grasp fold (Figure 1B and section 1.1.4). These ubiquitin-like proteins (Ubls) 
were found to behave in many ways like Ub, but require distinct enzymes and typically affect 
specific cellular functions.14 Among the best studied Ubls are SUMO – which governs 
transcriptional regulation and cell cycle progression among other functions, NEDD8 – which 
most prominently serves as activator of cullin-based E3 ligases, ISG15 – which was attributed 
anti-viral functions, and Atg12 – which is pivotal to formation of the autophagic pore. 
1.1.2 Homotypic ubiquitin chains 
Ubiquitin contains seven different lysine residues (K6, K11, K27, K29, K33, K48, and K63) as 
well as an N-terminus (M1), which can be targeted by ubiquitination (Figure 1B). This results 
in the assembly of polymeric Ub chains. Mass spectrometry studies revealed that all seven 
lysine residues and M1 serve as acceptor of Ub-conjugation in vivo.15 Abundances of chain 
types vary dependent on cell type, stage of cell cycle progression16 and exposure to stress 
conditions17. Historically, research on polyubiquitin has mostly focussed on homotypic Ub 
chains which are assembled exclusively through one linkage type. K48-linked polyubiquitin 
chains (“K48 chains”) are overall the most abundant species and were the first to be discovered.5 
Canonically, substrates decorated with these chains are targeted to the 26S proteasome for 
degradation.18 Assembly of K48 chains is an essential process and cells with K48 of Ub replaced 
with another amino acid are not viable.19 This is crucial for the removal of misfolded and 
unfolded proteins, which can potentially be toxic for the cell. Moreover, K48 chains are also 
required for acute regulation of cellular processes. For instance, misfolded proteins can be 
recognised and removed from the lumen of the endoplasmic reticulum by the HRD-ligase 
complex in a process called endoplasmic reticulum associated protein degradation (ERAD).20 
Based on folding and glycosylation status, this process is able to target a large variety of proteins 
for modification with K48 chains to induce their proteasomal degradation.21 In contrast, the 
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ordered transition through the cell cycle in eukaryotic cells requires timely controlled assembly 
of K48 chains for the degradation of specific cell-cycle proteins such as cyclins and securins.22 
Numerous enzymes assembling specifically K48 chains are known.5 
Shortly after the discovery of K48 chains, K63 was also identified to be prominently involved 
in polyubiquitin chain formation.23 Together, these two types of linkages account for the 
majority of polyubiquitin in cells.24 In contrast to K48 chains, K63 chains were found to 
promote functions mostly unrelated to proteasomal degradation. They can facilitate complex 
assembly and thereby govern widespread processes such as DNA damage repair23,25 
transcriptional activation26,27, innate immune responses28, endocytosis29,30,31 or protein 
trafficking32,33. Unanchored K63 chains were identified to promote cellular responses 
independently from any substrates.34,35 Moreover, K63 chains play a central role in assembly 
of autophagosomal pores for macroautophagy – the degradation of protein aggregates and/or 
subcellular organelles in the lysosome. For example, this is required for the clearance of 
damaged mitochondria.36,37 Among other proteins, the E2 enzyme Ubc13 has been shown to 
selectively assemble K63 chains by forming a hetero-dimer with the ubiquitin-conjugating 
enzyme variant Mms2 (or Uev1a), which lacks a canonical active site.38,39 Its activity was 
shown to play a crucial role in DNA damage repair.40 
Ub chains linked through other residues than K48 and K63 are often termed atypical Ub chains. 
Between these, M1 chains and K11 chains are the best studied. M1 chains were found to be 
quickly synthesised in the context of inflammatory signalling cascades41,42, whereas K11 chains 
also mediate protein degradation through the proteasome, particularly in the context of cell-
cycle progression43,44. Although data on the remaining Ub chain types is scarcer, proteins able 
to assemble and specifically recognise these exist. K6 chains have been identified in the process 
of removing damaged mitochondria.36 K27 chains are implicated in regulating DNA damage 
repair and in autoimmunity.45,46 K29 chains were associated with proteasomal degradation but 
also with formation of neuroprotective aggregates.47,48 K33 chains are assumed to affect 
trafficking through the trans-Golgi network.49 In contrast to enzymes responsible for assembly 
of K63, K48, K11 and M1 chains, enzymes associated with these atypical chains appear to 
exhibit less linkage specificity, i.e. they are capable of assembling Ub chains with multiple 
different linkages.36,50,51 
The signalling output of a Ub chain is not only determined by its linkage but also by its length. 
A longer Ub chain contains more interaction sites for downstream effectors and thus may 
provide a more potent signal. For instance, multiple small substrates are degraded efficiently 
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by the proteasome upon modification with short Ub chains or even monoubiquitination.52 
However, larger substrates require longer K48 chains which putatively provide a stronger 
degradation signal.53 In other cases, a hard threshold for length may exist for a specific 
interaction or process to occur. For example, the deubiquitinating enzyme MINDY has been 
found to only effectively cleave K48 chains which consist of at least four Ub molecules.13 A 
first global assessment of Ub chain length distribution in yeast revealed that Ub chains 
predominantly exist in dimeric to heptameric form.54 
1.1.3 Heterotypic ubiquitin chains 
Although research has mostly focussed on the biological function of individual types of Ub 
chains, different linkages can also be combined into a single Ub polymer. This includes Ub 
chains with alternating linkage types – “mixed chains” – and Ub chains with a moiety that is 
targeted at multiple lysine residues within a single Ub moiety – “branched chains” (Figure 1D). 
Few biological processes dependent on mixed and branched chains are addressed in the 
literature. Chains with alternating linkages have been identified in the context of NF-κB 
signalling.55 In this pathway K63 chains, which are attached to a substrate, are extended with 
M1 chains by the E3 LUBAC. A kinase complex can then associate with the M1 chains to 
phosphorylate components of another protein complex that is brought into proximity through 
interaction with the adjacent K63 chain. Moreover, subsequent studies suggested that this might 
protect the linear chains from disassembly by DUBs.56 K11/K48 branched chains generated by 
the anaphase-promoting complex (APC/C) have been shown to accelerate proteasomal 
degradation of cell-cycle regulators as compared to homotypic K48 chains.57 In recent years, 
Ohtake et al. demonstrated the existence of K48/K63 branched Ub chains in mammalian cell 
lines. They identified this signal to affect NF-kB signalling58 and the balancing of 
autophagosomal and proteasomal degradation59. Further developments in mass spectrometric 
methods are required to systematically investigate branched Ub chains, which might help 
understand the significance of signals combining differently linked Ub chains. While some 
studies suggest that branched and mixed chains merely connect different signals to which 
interactors can bind independently55,60, they might also confer unique binding interfaces for 
specific interactors. If and how branched and mixed Ub chains differ from the building blocks 
they are made of remains undetermined. 
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1.1.4 Structure of ubiquitin 
The structure of monoubiquitin and Ub chains defines the signals of the Ubiquitin Code. Ub is 
highly conserved among species. Only three amino acids differ between the human and yeast 
orthologue in S. cerevisiae (P19S, D24E, S28A). This indicates high evolutionary pressure to 
maintain the structure of Ub reflecting its central position in a network of many interactors. 
This also implies most of its surface residues are involved in binding interaction partners. 
Binders most prominently associate with a cluster of amino acids located around I44-L8-V70, 
called the hydrophobic patch (Figure 2A, blue).61 Another less prominently described 
hydrophobic surface clusters around I36-I71-I73 and also includes L8 (Figure 2A, green).61 Ub 
shows a highly stable β-grasp fold, in which a hydrophobic core is formed between an alpha 
helix (Figure 1B, orange) and a beta sheet with three strands (Figure 1B, yellow).62 Two regions 
of increased flexibility are known in the otherwise rigid fold of Ub. One is the β1/β2 loop 
spanning amino acids 6-10 (aa6-10, Figure 2A, orange), which notably harbours L8 – a 
constituent of the hydrophobic patch. The conformational equilibrium of this loop affects 
binding to interactors.63 Secondly, the last six amino acids of Ub confer a flexible C-terminus 
(Figure 2B), which allows many different conformations between Ub and its attachment site.64 
The side chains of the seven lysine residues and the M1 terminus, which are required for chain 
formation, are solvent exposed. Only K27 is partially buried and not optimally accessible.65 
To understand the distinct biological functions of differently linked Ub chains, structural 
differences between chain types have been extensively studied. X-ray crystallography 
experiments show that many diubiquitin molecules adopt compact conformations, in which the 
individual moieties tightly interact.66,67,68,69 K48 chains prominently adopt a closed 
conformation, in which the hydrophobic patches around I44 of both moieties form an 
intramolecular interface (Figure 2C). In contrast, M1 chains and K63 chains predominantly 
adopt an extended open conformation, in which the isopeptide bond between the two moieties 
is the only contact site (Figure 2D). However, structures of diubiquitin molecules showing 
alternative conformations as well as experiments investigating the flexibility of Ub chains in 
solution indicate that each Ub chain can dynamically sample a wide landscape of 
conformations.70,71 Computer simulations were used to shed some light into the frequency, with 
which the different chains adopt specific states in solution72 (Figure 2E). Addressing the 
dynamics of the conformational space of Ub chains experimentally is a challenging endeavour, 
which might be necessary for a detailed understanding of linkage selective Ub binders and their 
ability to discriminate between differently linked chains. As part of a collaborative project, 
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partners from the Goethe University in Frankfurt devised a method to investigate this 
question. Together, we explored how Ub binders affect chain topology and in turn how this 
affects enzymes interacting with these Ub chains. 
 
Figure 2: Structure of monoubiquitin and ubiquitin chains. (A) The hydrophobic patches around I44 (blue) 
and I36 (green) are highlighted in the three dimensional structure of Ub. (B) An NMR ensemble of Ub in solution 
highlights the flexibility of the C-terminal amino acids L71 through G76 (PDB: 2K39). (C) Crystal structure of 
K48-linked diubiquitin66 (PDB: 1AAR). (D) Crystal structure of K63-linked diubiquitin (PDB: 3H7P). 
(E) Landscape of diubiquitin conformations was explored by computer simulations. (E adapted from Wang et al.72)  
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1.1.5 Reading the Ubiquitin Code – ubiquitin binding domains (UBDs) 
To translate the Ub signals into specific biological outcomes, substrates decorated with Ub 
interact with downstream acting proteins which often contain ubiquitin binding domains 
(UBDs).73 More than twenty families of these domains with different binding specificities and 
diverse structures have been described.74 While most UBDs bind to the hydrophobic patch 
around I44 in Ub, the footprint they leave on the surface of Ub differs.75 Many UBDs show 
extremely low binding affinity for Ub with dissociation constants, which can reach into a high 
micromolar and even low millimolar range.76 Binding events between low affinity UBDs and 
Ub have been described to be among the weakest protein-protein interactions in nature, which 
are still considered specific.77 This might be due to the relatively high concentrations of Ub 
inside the cell78 and the requirement for quick reversibility of binding as part of a signalling 
process. 
Several mechanisms are known, through which Ub binding proteins can discriminate between 
different Ub chain types. For example, a single-domain UBD can simultaneously bind to two 
linked Ub molecules in a sandwich-like manner. This has been reported for the binding of 
Rad23A to 48Ub2.81 Alternatively, multivalent Ub binding interfaces can exploit the distance 
between Ub moieties within a chain. For instance, in the course of DNA double strand breaks 
Rap80 recognises K63 chains through two ubiquitin interacting motifs binding in tandem.79 
Similarly, the DUB OTUB1 features two distinct Ub binding sites in order to specifically 
recognise and cleave K48 chains.80 We found catalytically inactive OTUB1 to be a particularly 
strong binder and exploited this in control experiments. 
UBDs have been mostly studied as part of effector proteins which decode Ub signals into a 
cellular response. However, it is becoming increasingly clear that UBDs and other Ub binders 
fulfil pivotal roles in aiding the activity of chain building enzymes. For example, the E2 
enzymes Ubc1382 and Cdc3483 rely on such Ub binding events for their activity. Moreover, the 
E2 enzyme Ubc7 requires the Ub binding cofactor Cue1 to efficiently assemble K48 chains.84 
Ub chain assembly requires coordination of a substrate, a growing chain and the associated 
enzymes. How exactly Ub binding facilitates this spatially dynamic process remains poorly 
understood. During my doctoral research, I studied molecular mechanisms of Ubc7 activation 
through Cue1 and activation of the E2 enzyme Ubc1 through its intrinsic UBA domain. The 
CUE domain in Cue1 and the UBA domain in Ubc1 belong to UBD families which show low 
sequence similarity. However, they share a common structure which is composed of a bundle 
of three alpha helices and associates with the hydrophobic patch in Ub.85,86 In the following 
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section, I describe general properties of enzymes associated with Ub chain assembly, before 
outlining current knowledge on Ubc7 and Ubc1. 
1.2 Writing the Ubiquitin Code 
1.2.1 The ubiquitination cascade 
Modification of substrates with Ub requires the coordinated and sequential activity of ubiquitin-
activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3). They 
cooperate in an energy consuming process termed ubiquitination cascade (Figure 3A).4 In a first 
step which is driven by ATP-hydrolysis, a thioester bond between the sulfhydryl group of the 
active site cysteine in the E1 enzymes (UBA1) is formed with the free carboxyl group of the 
C-terminal G76 in Ub. The UBA1/Ub thioester (UBA1~Ub) then exposes a binding site, 
through which E2 enzymes can be recruited for a transthiolation reaction, in which Ub is 
transferred to the active site cysteine of the cognate E2 enzyme.87 For the final step of 
ubiquitination, the E2 enzyme, which is charged with Ub (E2~Ub), typically cooperates with 
an E3 ligase, which are canonically categorised into three different families.4 In a transthiolation 
reaction, E2~Ub can transfer Ub to HECT- or RBR-E3-ligases which harbour an active site 
cysteine themselves and consecutively engage with a substrate.88,89 Alternatively, E2~Ub can 
associate with RING ligases. These account for the majority of E3 ligases.90 The RING ligase 
mediates substrate recruitment and binds E2~Ub in a way which facilitates discharge. As a 
result, Ub is transferred onto a target lysine in the substrate. Recent studies suggest that 
specialised E2 and E3 enzymes are capable to transfer Ub to hydroxyl groups in serine or 
threonine residues.91,92 Because E3 ligases typically confer substrate specificity, they have been 
a prominent object of research. However, it is becoming increasingly clear that E2 enzymes 
frequently are the deciding factor for linkage type and spatial organisation of the Ub signal.93 
1.2.2 Structure of E2 ubiquitin-conjugating enzymes 
The structure of E2 enzymes is defined by a catalytic core domain (“UBC domain”) of about 
150 amino acids and has been reviewed in detail93 (Figure 3B). The UBC domain consists of a 
β-sheet of typically four antiparallel β-strands, which is flanked by four α-helices. The active 
site cysteine is located in a loop region which connects the C-terminus of the β-sheet (strand 
β4) with helix α2. Beta strand β4 is shortly followed by a conserved HPN triad, which is 
reported to be required for enzymatic activity. Helix α2 is also termed „crossover helix“ as it is 
positioned across the β-sheet. A “gateway residue”, which is located at the N-terminal end of 
helix α3, has been reported to regulate the activity of a number of E2 enzymes.94,95,96 The 
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surface opposite to the catalytic site has been found to mediate “backside binding” of the E1 
enzyme and regulatory factors such as RING domains or Ub itself (Figure 3B). Many E2 
enzymes show variations of this pattern with C-terminal or N-terminal extensions or distinct 
insertions within the UBC domain. E2 enzymes charged with Ub (E2~Ub) can adopt a distinct 
closed conformation, in which the donor Ub (UbD) binds through its hydrophobic patch to the 
crossover helix in the UBC domain (Figure 3C,D).97 This conformation was identified to be 
stabilised by the binding of RING domains and to be pivotal to enzymatic activity.98  
 
Figure 3: E2 ubiquitin-conjugating enzymes. (A) During the ubiquitination cascade, E2 enzymes are charged 
with Ub by E1 enzymes in an ATP consuming first step. Ub is transferred from the E2/Ub thioester to target 
proteins through aminolysis, transthiolation or esterification. (B) Structural features of E2 enzymes. (C) E2 
enzymes charged with Ub adopt open and closed conformations. The latter are particularly important for enzymatic 
activity. (D) Structure of E2~Ub in closed conformation. (B-D adapted from Stewart et al.93) 
Some E2 enzymes target a wide substrate pool, while others target specific residues in particular 
proteins. For example, Ubc6 does not only mediate the degradation of a wide range of mostly 
misfolded proteins in the context of ERAD, it is also capable of targeting serine and threonine 
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residues highlighting its high promiscuity.91 In contrast, E2 enzymes, which are involved in Ub 
chain assembly, typically target a specific lysine residue within Ub. Accordingly, the UBC 
domains of these E2 enzymes have been found to interact with the acceptor Ub (UbA) in specific 
ways. For example, a number of acidic residues in the UBC domain of Ube2S have been found 
to align UbA to mediate its specificity for K11.99 However, chain assembling E2 enzymes have 
been found to interact with acceptor Ub (UbA) very weakly. For instance, the KM value of the 
K63 specific Ubc13 or Mms2 to UbA has been quantified to 437 µM, which is indicative of its 
low binding affinity.100  
1.2.3 E2 ubiquitin-conjugating enzyme Ubc7 
The activity of the E2 enzyme Ubc7 is closely intertwined with its co-factor Cue1. Cue1 is a 
membrane anchored multi domain protein. It contains an N-terminal transmembrane helix, a 
Ub binding CUE domain and the Ubc7 activating binding region (U7BR) at its C-terminus. In 
absence of Cue1, Ubc7 is autoubiquitinated and degraded.101 Cue1 and Ubc7 are essential 
components of the ERAD pathway.102 Cue1 is required to recruit Ubc7 to the Hrd1-ligase 
complex – a central component of ERAD – and to activate Ubc7 via its U7BR-domain through 
backside binding.103 Ubc7, like the homologous E2 enzyme Ube2g2, contains an acidic loop 
close to the C-terminus of the crossover helix, which endogenously adopts an alpha helical fold 
and thus obstructs the active site (Figure 3B). Co-factor binding leads to conformational 
changes in this region and thereby an activation of the enzyme.104 Additionally, the CUE-
domain of Cue1 binds to Ub and thereby facilitates assembly of K48-linked polyubiquitin by 
Ubc7.84 Disrupting this interaction reduces degradation of Ubc7 substrates in vivo. Herein, I 
present how Ub binding by the CUE domain can stimulate Ub chain assembly on a molecular 
level. 
1.2.4 Biological processes affected by the E2 enzyme Ubc1 
Stimulated by the work on Ubc7, I aimed to look for other E2 enzymes, for which Ub binding 
could activate Ub chain assembly. A prominent candidate was Ubc1 which among yeast E2 
enzymes uniquely harbours a UBD – specifically a ubiquitin associated domain (UBA 
domain).105,106 When it was discovered, Ubc1 was found to be involved in protein turnover, to 
mediate resistance to proteotoxic stress induced by canavanine, to be vital for cell growth and 
to be essential for survival in yeast deleted for ubc4.107 Later, it was found to selectively 
assemble K48 chains and prominently undergo autoubiquitination at K93 close to the active 
site (C88).108 Ubc1 has been shown to be phosphorylated at S97 and S115 by mitogen-activated 
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protein (MAP) kinases.109 This propensity appears to influence tolerance to thermal and 
reductive stress in S. cerevisiae. Ubc1 and Ubc4 were shown to act cooperatively in the 
degradation of substrates of the anaphase promoting complex (APC/C).110 In this process, Ubc4 
has been identified to promiscuously attach monoubiquitin to the targeted substrates, which can 
then be extended to K48 chains through the activity of Ubc1. Ubc1 can weakly replace Ubc4 
activity in context of APC/C, but Ubc4 cannot replace Ubc1.111  
Moreover, Ubc1 homologues have been implicated in the clearance of protein aggregates and 
in the development of neurological diseases. Accumulation and insufficient clearance of protein 
aggregates in neuronal cells is a shared mechanism for pathogenesis, observed in many 
neurodegenerative diseases as for instance in Alzheimer’s disease (AD), Parkinson’s disease 
(PD) and Huntington’s disease (HD).112 Accordingly, it has become increasingly clear that the 
cellular folding machinery as well as regulated protein degradation play pivotal roles in the 
development of these diseases.113 For example, model systems for the study of mutant 
huntingtin protein (Htt) show that Htt can be degraded either through proteasomal degradation 
mediated by K48 chains or through the autophagosomal pathway induced by K63 chains.114 
The human Ubc1 homologue Ube2K has been implicated in PD115 and HD116,117. In model 
systems used to study these diseases, Ube2K was found to increase cell death through its 
catalytic activity.115 
A direct link between the activity of Ube2K in the context of protein quality control and 
neurodegenerative diseases could thus far not be established. However, growing evidence 
points to the importance of the cellular folding machinery, molecular chaperones and protein 
quality control pathways to keep these diseases in check.113,118 For example, in AD, PD and HD, 
overactivation of the unfolded protein response (UPR) is commonly observed.119,120 This stress 
response, which is conserved among all mammals as well as yeast and worm organisms, is 
activated upon accumulation of misfolded and unfolded proteins in the ER lumen. Its activation 
ultimately provokes the production of chaperones, the inhibition of protein translation and an 
increased degradation of misfolded proteins. Prolonged UPR activation may induce 
apoptosis.121 To investigate the putative functions of Ubc1 in protein quality control, we 
collaborated with the group of Dr. Janine Kirstein from the Leibnitz-Institute for Molecular 
Pharmacology (FMP), Berlin. Dr. Kirstein uses elaborate C. elegans model systems to study 
proteostasis and more specifically, how molecular chaperones, the ubiquitin proteasome system 
as well as autophagy combat protein aggregation in aging and disease. 
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1.2.5 Structural features of Ubc1 
Several key residues governing the activity and K48 selectivity of the UBC domain in Ubc1 
and its human homologue Ube2K (E2-25K/HIP2) were identified. Where other E2 enzymes 
commonly contain a leucine or alanine residue as “gateway residue” as outlined in section 1.2.2 
(Figure 3B), Ubc1 contains glutamine (Q122). Substitution of the corresponding glutamine 
residue in Ube2K (Q126) to leucine facilitates aminolysis of the E2~Ub thioester putatively by 
improving the accessibility of the active site. However, this amino acid substitution 
simultaneously interferes with the K48 specificity of the enzyme.122 Y59 in UbA has been 
identified to be crucial for K48 specificity and enzymatic activity of Ubc1.123 A study on Ube2K 
shows that Y59L in Ub could partially rescue impaired diubiquitin formation by Ube2K-
Q126L, indicating a critical interaction between Q126 in Ube2K and Y59 in Ub.124 Moreover, 
the authors show that K97E substitution in Ube2K, which also impairs diubiquitin formation, 
could in turn be rescued by E51R substitution in Ub. Based on their mutagenesis studies and 
structural modelling they propose that association of Ube2K with UbA is stabilised by an 
interaction interface between an area in Ube2K with several polar residues (S85, S86, T88, 
D127) and an acidic loop in UbA spanning from D58 to Q60. 124 In line with these findings, T84 
and Q122 in Ubc1 are vitally important for K48 selectivity and Ubc1 activity in cell cycle 
progression.123  
Despite thorough investigation of Ubc1 and its homologues, little is known about the function 
of the prominent C-terminal extension of helix α4, which harbours the Ub binding UBA 
domain. It adopts a compact fold of three short alpha helices typical for this family of UBDs. 
A solution NMR structure of full length Ubc1 suggests high flexibility in the linker region 
connecting the UBC domain and the UBA domain.105 Moreover, mapping of the residues 
involved in Ub binding by NMR spectroscopy revealed that the interaction occurs in a 
conserved way between helices α1 and α3 in the UBA domain and the hydrophobic patch in 
Ub. The structure indicates that interaction between the UBA domain and UbD is unlikely, which 
was also suggested by other studies.111,125 Based on qualitative activity assays, the UBA domain 
is thought to enhance processivity during assembly of K48 chains in vitro.126 Although Ubc1 
and its human homologue Ube2K (or HIP2/E2-25K) have been implicated in a number of 
biological processes, the functional significance of the UBA domain is poorly understood. The 
main goal of my work was to elucidate whether and how the UBA domain facilitates Ub chain 
synthesis by Ubc1.  
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1.3 Polyubiquitin nomenclature in this work 
Few conventions on naming polyubiquitin chains have emerged. Most importantly, the Ub 
moiety attached to a substrate or with a free C-terminus in unanchored chains is referred to as 
the proximal Ub, while the moiety at the end of the chain, to which no more Ub is attached, is 
named distal Ub. However, no systematic nomenclature for polymers of Ub or ubiquitin-like 
proteins has been widely adopted. As increasingly complicated Ub structures become subject 
to study, an easy way to discuss complex polyubiquitin topology would be valuable. Ultimately, 
a unified machine-readable code would greatly benefit the study of Ub signals in silico. This 
section explains the abbreviations used for polyubiquitin in this thesis (Figure 4). 
A system previously suggested by Nakasone et al. works similar to condensed structural 
formulas used in organic chemistry60 (Figure 4A, “condensed”). All Ub molecules of a polymer 
are listed similar to the atoms of an organic molecule and linkage types are indicated between 
them. Branching points are described through brackets, which entails limited readability for 
complex chains. I suggest a simplification for nomenclature, which exploits the directional 
structure of polyubiquitin: Ub polymers are canonically linked through their C-terminus and 
thus form hierarchically ordered trees. This means each polymer contains a single root – the 
proximal Ub moiety. From this root, one or more paths of subsequently added Ub molecules 
emerge. The linkage types between the Ub monomers define each path. All paths end in a “leaf” 
– a moiety to which no further Ub is attached. Such a tree can be unambiguously described by 
specifying the paths to its leafs, i.e. by enumerating the sequence of linkages from the proximal 
Ub to every distal Ub. 
In this work, Ub chains will be written as “path(s)Ub#Ub” or “path(s)Ub#P(mut)”, where “path(s)” 
lists the sequence of linkages from proximal to distal Ub separated by commas (Figure 4B,C). 
For branched chains, multiple paths exist, which are separated by a slash symbol. Identical 
linkages in sequence (e.g. “K48,K48,K48”) can be abbreviated as multiplication indicated with 
“x” (i.e. “K48x3”). Optionally, “#Ub” in subscript is included to improve readability by 
indicating the number of Ub units in a chain (i.e. the length for unbranched chains). “#P” is a 
pointer that indicates specific moieties along a path in form of a number, a list of numbers 
separated by commas, a range defined by a minus symbol, or a list of ranges. The number 
indicates the position of the specified Ub moiety along the path, where 1 is the proximal moiety. 
The pointer is followed by a statement (“mut”) in brackets, which contains residue specific 
information such as amino acid substitutions or labels. An advantage of this system is that 
topology and listing of substitutions or modifications can be separated and that different 
1. Introduction 
15 
statements can unambiguously describe the same Ub chain. This is especially useful for 
complex polymers and provides leeway to highlight specific features of a Ub chain. 
 
 
Figure 4: Notation of Ub chains in this work. (A) The topology of every Ub polymer can be fully described by 
enumerating all paths, i.e. the sequence of linkages from the proximal moiety (“root”) to each distal moiety 
(“leaf”). Condensed sum formula indicated with an asterisk describes the notations suggested by Nakasone et al.60 
(B) Formulas used in this work to name polyubiquitin molecules. (C) Pointers indicate residue specific information 
such as the location of the R42A substitution. 
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1.4 Aims of this study 
The aim of this study is to explore how Ub binding interfaces can stimulate the assembly of 
polyubiquitin chains, specifically in the context of the activity of E2 ubiquitin-conjugating 
enzymes. To this end, the two E2 enzymes Ubc1 and Ubc7 should be studied. Both enzymes 
rely on associated Ub binding domains (UBDs) for stimulation. K48 chain assembly through 
Ubc7 relies on activation through the co-factor Cue1 which harbours a Ub binding CUE 
domain.84 Similarly, the Ub binding UBA domain in Ubc1 is thought to promote K48 chain 
assembly by Ubc1126, although this is still under debate due to conflicting results of several 
studies123,127. How exactly Ub binding facilitates the activation of these systems remained 
elusive. 
The following objectives were set: 
 Investigate CUE domain specific activation of Ubc7 by Cue1 in collaboration with 
Dr. Maximilian von Delbrück (MDC, Berlin) and Dr. Andreas Kniss (Goethe 
University, Frankfurt). 
 Elucidate whether the UBA domain of Ubc1 facilitates Ub chain formation. 
 Investigate mechanistic details of Ubc1 activity in the context of its UBA domain. 
 Identify cellular processes affected by this activity and study their biological outcome. 
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2. Results 
2.1 Binding of ubiquitin by Cue1 enables rapid elongation of 
K48 chains by Ubc7 
2.1.1 The CUE domain of Cue1 facilitates assembly of K48-linked 
polyubiquitin chains by binding to the penultimate Ub moiety 
Previous studies show that the E2 ubiquitin-conjugating enzyme Ubc7 relies on association 
with its Ub binding cofactor Cue1 for activation.84 However, the exact mechanism of how Ub 
binding can stimulate Ub chain elongation remained largely unclear. To elucidate factors 
contributing to CUE domain mediated chain elongation through Ubc7, we performed in vitro 
ubiquitination experiments with Ubc7 and the cytosolic fragment of Cue1 (Ubc7/Cue1) in 
presence of fluorescent donor Ub and different acceptor Ub molecules, which were C-
terminally hexahistidine-tagged (Figure 5). Ubc7 targets K48 in Ub exclusively and, thus, only 
the distal moiety in K48 chains. Therefore, K63 chains used in the experiment harboured 
Ub(K48R) in all moieties except the distal one. The substrate turnover was observed by 
fluorescence anisotropy and average initial reaction rates were calculated from three 
experiments. Reactions were faster for longer Ub chains than for shorter chains and faster for 
K48 chains than for K63 chains (Figure 5A). 
To investigate whether binding to specific positions within a K48 chain is necessary for 
Ubc7/Cue1 activity, we performed in vitro ubiquitination experiments, before which the CUE 
domain was cross-linked to distinct Ub moieties within K48-linked diubiquitin (48Ub2) or 
triubiquitin (48x2Ub3) (Figure 5B). Cross-linking the CUE domain to the proximal position in 
48Ub2 led to the fastest Ub turnover, while cross-linking to the proximal position in 48x2Ub3 led 
to slightly slower turnover. In contrast, cross-linking of the CUE domain to the distal position 
in 48Ub2 reduced reaction rates as compared to non-cross-linked components (Figure 5B). In 
summary, this shows that Ubc7 is optimally activated through binding of the CUE domain to 
the penultimate moiety in a K48 chain. 
To corroborate these findings, we aimed to perform single turnover ubiquitination experiments 
with acceptor Ub deficient in binding to the CUE domain. As R42 in Ub is pivotal for interaction 
with the CUE domain (see below), we introduced Ub(R42A) into different positions of K48-
linked tetraubiquitin (48x3Ub4) and performed single turnover ubiquitination experiments as 
described above. Introduction of Ub(R42A) into the penultimate moiety of 48x3Ub4 reduced 
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Figure 5: Binding of the CUE domain of Cue1 to the penultimate moiety in K48 chains stimulates chain 
assembly by Ubc7. (A) Initial reaction rates were determined for single turnover ubiquitination experiments with 
Ubc7/Cue1 in presence of different Ub chains as acceptors. (B) In vitro ubiquitination experiments were performed 
with Ubc7 and Cue1 T66C C147S, which was cross-linked to different Ub chains containing Ub(T9C). Cue1 was 
cross-linked to the proximal position in 48Ub2 (light green), 48x2Ub3 (red) or to the distal position in 48Ub2 (dark 
green). A reaction with equimolar amounts of Cue1 and 48Ub2 was performed as reference (orange). (C) Single 
turnover ubiquitination experiments as in A were performed in presence of 48x3Ub4 as acceptor with Ub(R42A) in 
different positions. (D) The experiment in C was repeated with 48x3Ub4 harbouring an increasing amount of 
Ub(R42A) moieties. Error bars show average and SEM of three experiments. Figure adapted from von Delbrück 
et al.1 Experiments performed by Dr. Maximilian von Delbrück. 
kinetic rates the most, while Ub(R42A) located at the proximal moiety had the smallest impact 
(Figure 5C). Additional Ub(R42A) moieties in a Ub chain with Ub(R42A) at the penultimate 
position cause a further reduction of kinetic rates (Figure 5D). Proposedly, Ub binding by Cue1 
activates Ubc7 not only by arranging the involved proteins in an energetically favourable way, 
but also by increasing the local concentration of the enzyme near its substrate. 
To investigate binding of the CUE domain towards K48 chains, we created K48- and K63-
linked diubiquitin molecules, which were 15N-labeled, either at the proximal or distal position. 
These probes were then applied to NMR titration experiments with the CUE domain. Chemical 
shift perturbations (CSPs) in Ub upon binding showed that the residues I44, L8, V70, R42, G47 
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Figure 6: G75 in the proximal moiety of 48Ub2 contributes to an enhanced binding interface with the CUE 
domain. Chemical shift perturbations (CSP) were quantified for the backbone amides in (A) 48Ub2 and (B) 63Ub2 
respectively upon binding of the CUE domain to the proximal (blue) or the distal Ub moiety (red). The CSP for 
R42 is marked with an asterisk and arbitrarily set to 0.5. The signal for this residue disappeared during titration 
with the CUE domain and therefore its CSP could not be determined. 15N-1H-HSQC spectra were recorded at a 
1:1 molar ratio of (C) CUE:48Ub2 and (D) CUE:63Ub2 for either proximally (blue) or distally (red) labelled Ub2 as 
well as for Ub2 (black) in absence of CUE domain. A representative section is shown. The CSP of I44 was plotted 
over the concentration ratio of CUE domain over (E) 48Ub2 and (F) 63Ub2 respectively. Kd values for binding of the 
CUE domain were determined assuming two independent but different binding sites. Figure as published in von 
Delbrück et al.1 Sample preparation was performed jointly. NMR titration experiments and analyses were 
performed by Dr. Andreas Kniss.  
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and L71 were prominently involved in binding. They cluster around the hydrophobic patch in 
Ub. Interestingly, the CSP of G75 in the distal moiety in 48Ub2 showed a significantly larger 
CSP than in the proximal moiety (Figure 6A), which could not be observed for 63Ub2 (Figure 
6B). This indicates that G75 in the distal Ub enlarges the binding interface between the CUE 
domain and the proximal moiety in 48Ub2.  
Accordingly, an overlay of the 15N-1H-HSQC spectra at a 1:1 molar ratio of CUE:48Ub2 revealed 
distinct CSPs between the individual moieties for residues involved in binding (Figure 6C). 
Residues in the proximal moiety of 48Ub2 showed stronger CSPs than corresponding residues 
in the distal moiety as compared to unbound 48Ub2. Such a difference could not be observed for 
63Ub2 (Figure 6D). We determined Kd values based on the CSP of I44 in Ub at different 
concentrations of diubiquitin and CUE domain (Figure 6E and F). The CUE domain showed a 
two-fold increase in binding affinity towards the proximal Ub in 48Ub2 over other Ub moieties 
(Figure 6E and F). In other words, Cue1 preferentially associates with Ub moieties within a 
K48 chain over the distal one. This preference mirrors the binding sites for the CUE domain, 
which we showed to be optimal for Ubc7 activation. 
Based on the NMR binding studies, we created a set of Cue1 variants with amino acid 
substitutions E96A, E100A and L103A, which showed increasingly lower binding affinities for 
Ub as measured by CSPs of V73, L76 and A77 (Figure 7A). We assessed the ability of these 
variants to promote Ub chain formation by Ubc7 in single turnover ubiquitination experiments 
(Figure 7B). To this end, elongation of 48x3Ub4 with fluorescently labelled monoubiquitin by 
Ubc7/Cue1 was monitored by fluorescence anisotropy in the presence of Hrd1 RING-domain. 
Quantification of initial rates for the different variants correlates with CSPs observed in binding 
experiments (Figure 7A,B). 
Next, we aimed to investigate the impact of the amino acids substitutions on Ubc7 activity in 
the living cell. Thus, constructs, which induce the expression of the Cue1 variants, were 
introduced into S. cerevisiae deleted for endogenous cue1. Subsequently, the degradation of 
Ubc6, which is dependent on Ubc7 activity84, was analysed in cycloheximide chase assays 
(Figure 7C). We employed constructs encoding wild-type Cue1 or binding deficient Cue1 
(Cue1-RGA) as references. Cue1-RGA, in which the LAP motif (aa76-78) was substituted for 
RGA, was previously shown to harbour an unfolded CUE domain.84 Protein degradation was 
chased for three hours. Samples were analysed by SDS-PAGE and western blotting with the 
indicated antibodies. Sec61 served as input control. All Cue1 constructs showed equal 
expression levels and were not degraded during the chase (Figure 7C). Ubc6 degradation was 
2. Results 
21 
strongly impaired in yeast harbouring Cue1-RGA, while the Cue1 variants with moderately 
reduced binding affinity caused impaired Ubc6 degradation (Figure 7D). Evidently, gradual 
decrease of binding affinity of the CUE domain for Ub correlates with impeded chain 
elongation activity in vitro and substrate turnover in vivo. 
 
 
Figure 7: Reduced binding affinity of the CUE domain to Ub correlates with an impaired ability to stimulate 
Ubc7 activity in vitro and in vivo. (A) CSPs of V73, L76 and A77 in Ub were measured in NMR titration 
experiments at a 1:8 molar ratio of CUE domain to Ub. CSPs for different Cue1 variants were normalised to wild-
type. Experiment performed by Dr. Andreas Kniss. (B) Initial reaction rates with 48x3Ub4 were determined in single 
turnover ubiquitination experiments with Ubc7 and different Cue1 variants in presence of the Hrd1 RING-domain. 
Average of three experiments. Error bars are SEM. Experiment performed by Dr. Maximilian von Delbrück. (C) 
The degradation of the ERAD substrate Ubc6 was observed in S. cerevisiae expressing different Cue1 variants by 
cycloheximide chase assays. Samples were taken at the indicated time points and analysed by SDS-PAGE and 
western blotting with the indicated antibodies. (D) Band intensity for Ubc6 from C was quantified, normalised to 
the starting time point, averaged for each construct over a triplicate and plotted over time. Error bars indicate SEM. 
Data from a separate experiment was included, which shows degradation of Ubc6 in yeast deleted for ubc7 (black) 
or cue1 (gray). Figure modified from von Delbrück et al.1 
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2.1.2 Binding of the Cue1 CUE domain to K48 chains relies on 
conformational selection 
 
Figure 8: Ub binding proteins differently affect the conformational space of 48Ub2. A conformational ensemble 
of 48Ub2 was obtained through PELDOR spectroscopy and molecular modelling. The proximal Ub is shown in 
grey, while the position of the distal Ub is depicted as probability grid. (A) 48Ub2 in presence of Cue1 CUE domain 
with probability cut-offs at 0.12 (pink) and at 0.4 (red). (B) 48Ub2 in absence (blue) and presence (red) of Cue1 
CUE domain with probability cut-offs at 0.2. (C) 48Ub2 in presence of OTUB1-C91A with probability cut-offs at 
0.12 (light green) and 0.4 (dark green). (D) 48Ub2 in absence (blue) and presence (green) of OTUB1-C91A with 
probability cut-offs at 0.2. Figure adapted from Kniss et al.2 
Ub chains are flexible and may adopt variable conformations, which affects how Ub binding 
proteins can interact with these chains. We hypothesised this layer of regulation might be 
particularly important for proteins mediating assembly or disassembly of chains. To investigate 
conformational space of 48Ub2, PELDOR spectroscopy was combined with molecular 
modelling. In essence, PELDOR spectroscopy was used to record distance distributions 
between spin labelled amino acids introduced into the proximal and distal moiety of diubiquitin. 
Spectra were recorded for multiple spin label pairs located in different positions of 48Ub2. The 
distance distributions were then used as restrains and probability factors for structural modelling 
by CYANA 3.9. The weighted structure ensemble was visualised as probability grid of the 
position of the geometric centre of the distal Ub (aa1-71). This novel approach revealed that 
K48 chains adopt a wide conformational space, which includes the closed conformation66 
reported by X-ray crystallography as one of many possible conformations. The CUE domain of 
Cue1 was found to stabilise conformations, which are inherently adopted by 48Ub2 (Figure 
8A,B), whereas other binders, for example OTUB1, were found to remodel the conformational 
distribution of these chains (Figure 8C,D). 
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In order to examine how the binding mode of the CUE domain affects chain elongation by 
Ubc7, we performed single turnover ubiquitination experiments. A construct harbouring Ubc7 
as well as the activating U7BR-domain from Cue1 (Ubc7-U7BR) was devised to separate the 
Ub binding activity of Cue1 from its activating activity through the U7BR domain (Figure 9A). 
We tested the ability of this enzyme to extend K48-linked diubiquitin and tetraubiquitin in the 
presence and absence of different Ub binding proteins (Figure 9B). Fluorescently labelled 
monoubiquitin and C-terminally blocked acceptor Ub were used in a 1:10 molar ratio. Acceptor 
Ub was either K48-linked diubiquitin or tetraubiquitin. Samples were taken over 15 min and 
analysed by SDS-PAGE and fluorescence scans. Ub binders were added in a 2:1 molar ratio to 
Ub in reactions with diubiquitin and 4:1 molar ratio in reactions with tetraubiquitin. Next to the 
Cue1 CUE domain, we employed the CUE domain of the human homologue gp78. A previous 
study shows that this domain has a higher binding affinity for Ub and apparently does not 
promote the position specific binding observed for Cue1.128 The UBA2 domain of Rad23A 
preferentially associates with K48 diubiquitin by interacting with both moietites akin to Cue1 
but also binds with higher affinity.81 Ultimately, the K48 specific DUB OTUB1, which belongs 
to the Otubain protease family, was employed in the experiment by substituting the active site 
C91 with alanine. We found that all Ub binders impaired the elongation activity. This might 
occur due to obstruction of the acceptor K48 and/or through unfavourable conformational 
remodelling of the acceptor Ub chain. Quantification of initial reaction rates revealed a 
reduction of initial rates by ~30% in presence of the CUE domain whereas other binders 
diminish the initial rates by 70% or more (Figure 9C). Evidently, binding of Ub by the CUE 
domain minimally impairs chain elongation. 
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Figure 9: Ub binding proteins differently affect elongation of Ub chains by Ubc7-U7BR. (A) Overview of in 
vitro chain elongation reactions with Ubc7-U7BR. (B) In vitro chain elongation reactions with fluorescent donor 
Ub and 48Ub2 or 48x3Ub4 as acceptor were performed with Ubc7-U7BR in presence of different Ub binders. Samples 
were taken at the indicated time points and analysed by SDS-PAGE and fluorescence scan. Asterisk indicates 
diubiquitin, which is formed as product of a side reaction. (C) Fluorescence intensity of Ub3 or Ub5 over total 
fluorescence per lane was quantified from B and plotted over time. Initial reaction rates were determined as slope 
of a linear approximation and normalised to reaction rates without Ub binders. Error bars indicate average and 
SEM of three experiments. Figure adapted from Kniss et al.2 
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2.1.3 Putative Ubc7 dimerisation facilitates formation of diubiquitin 
During our analysis of chain elongation reactions by Ubc7-U7BR we observed formation of 
diubiquitin as a side reaction (Figure 9B, asterisk). This occurred despite the relatively high 
ratio of acceptor Ub (10 µM UbA) to donor Ub (1 µM UbD). We repeated the experiment with 
titrations of various reaction components. While changing the concentration of E1 enzyme had 
no impact on the pattern of reactions products (data not shown), reducing the concentration of 
E2 enzyme yielded higher amounts of diubiquitin (Figure 10A). Reduced Ubc7-U7BR levels 
should increase the ratio of Ubc7-U7BR charged with Ub (Ubc7-U7BR~Ub) to uncharged 
enzyme (Ubc7-U7BR) in the reaction. We hypothesised that a high ratio of Ubc7-U7BR~Ub to 
Ubc7-U7BR might facilitate diubiquitin assembly through dimerisation of Ubc7-U7BR~Ub 
(Figure 10B). In contrast, a higher concentration of Ubc7-U7BR leads to increased formation 
of dimers between Ubc7-U7BR~Ub and Ubc7-U7BR, which are apparently incapable of 
diubiquitin formation. Increased salt concentrations in the experimental setup led to a reduced 
formation of diubiquitin, while assembly of triubiquitin was only slightly impaired (Figure 
10C). This suggests that the dimer formation by Ubc7-U7BR charged with Ub, relies 
predominantly on electrostatic interactions. We aimed to validate our findings about the Ubc7-
U7BR fusion protein using wild-type Ubc7. Thus, Ubc7 was investigated in in vitro 
ubiquitination reactions with the same conditions, in presence of either wild-type Cue1 or its 
binding deficient RGA variant84 (Figure 10D). In both cases, formation of diubiquitin from UbD 
could be observed despite the ten-fold molar excess of UbA over UbD. However, in presence of 
wild-type Cue1 the assembly of triubiquitin was favoured, which can be attributed to 
acceleration of chain formation by the CUE domain. Analytical size exclusion experiments with 
Ubc7-U7BR(C89K) stably loaded with Ub showed salt concentration dependent elution 
profiles (Figure 10E). With lower ionic strength of the buffer the elution peak shifted toward 
fractions with higher apparent molecular weight, indicative of dimer formation.  
A Ubc7 variant, which is capable of chain elongation, but does not readily form diubiquitin, 
would be desirable to investigate the significance of Ubc7 dimerisation in vivo. Thus, we 
created multiple Ubc7-U7BR constructs harbouring mutations in sequences coding for amino 
acids in the acidic loop (D98, D99, E104, E107, E108) and charged residues close to the active 
site (R109, D146, R145). In vitro chain elongation reactions showed that the Ubc7-U7BR 
variants were impaired in diubiquitin and triubiquitin formation (Figure 10F) with the exception 
of Ubc7-U7BR(D146R), which showed hyperactive formation of both products. Future 
attempts to create Ubc7 variants with the desired probabilities should be preceded by additional 
structural investigation of Ubc7 dimer formation. Further analyses are required to evaluate the 
role of Ubc7 dimerisation in the living cell.  
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Figure 10: Putative Ubc7 dimerisation facilitates formation of diubiquitin. (A) In vitro chain elongation experiments 
were performed in presence of different concentrations of Ubc7-U7BR. Samples were taken at indicated time points and 
analysed by SDS-PAGE and fluorescence scan. (B) Schematic representation of reaction pattern observed in A. (C) 
Chain elongation reaction from A (right panel) was repeated in absence and presence of 150 mM NaCl. Fluoresnce 
intensity of reaction products was quantified and the ratio of Ub2 to Ub3 was calculated. Signal intensity for t=1 min was 
too low for quantification. (D) Chain elongation reaction from A (right panel) was repeated with wild-type Ubc7 and 
Cue1 or Cue1-RGA instead of Ubc7-U7BR. (E) Analytical size exclusion experiments with Ubc7-U7BR (C89K) stably 
loaded with Ub were performed by Dr. Andreas Kniss at different salt concentrations. Apparent molecular weights were 
calculated based on a calibrated Superdex 75 10/300 GL and are listed below the elution profiles. (F) In vitro chain 
elongation experiments with Ubc7-U7BR variants with different amino acid substitutions.  
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2.2 The UBA domain of Ubc1 facilitates the assembly of 
K48/K63 branched chains 
2.2.1 Structural analysis of Ubc1 
2.2.1.1 Analysis of existing structural information on Ubc1 and its homologue Ube2K 
Previous studies suggest that the UBA domain of Ubc1 assists in assembly of K48 chains 
through binding of Ub,112 while other reports challenge this observation.123,127 I aimed to 
analyse existing structural information on Ubc1105 and its human homologue Ube2K124,129,130,131 
in order to assess whether these enzymes might exploit a similar reaction mechanism to Ubc7 
and Cue1. Based on X-ray crystallographic data for Ube2K and HADDOCK modelling, an 
interaction interface between acceptor Ub (UbA) and the UBC domain has been proposed124 
(Figure 11A). This Ube2k/UbA complex was validated through mutagenesis studies and in vitro 
ubiquitination experiments.124 Interestingly, G76 in the modelled UbA is located on the opposite 
side relative to the position of the UBA domain (Figure 11B). This positioning is incompatible 
with the UBA domain binding to a proximal Ub moiety relative to the immediate UbA. Thus, 
this geometry presents a stark contrast to Ubc7/Cue1, which requires binding of the penultimate 
moiety in a Ub chain for activation. Several X-ray crystallographic structures of Ube2k are 
available from the protein databank (PDB: 5DFL, 6IF1, 3E46, 3F92, 3K9P). In all of these 
structures the UBA domain closely coordinates with the UBC domain through a hydrophobic 
interface.130 In contrast to this, an NMR solution structure of Ubc1 reveals high flexibility in 
the linker region of Ubc1 (aa151-167) located between the UBA domain and the UBC domain 
(Figure 11C). Despite this high flexibility, no conformation was observed that allows for the 
association of the UBA domain with a proximal Ub highlighting the contrast to Ubc7/Cue1. 
Lee et al.131 report a structure of Ube2K (PDB: 6IF1) in complex with 48Ub2, in which two 
Ube2K molecules are coordinated through their UBA domain with either the proximal or the 
distal moiety of the diubiquitin molecule respectively. Structural comparison of the Ube2K 
molecules reveals an identical conformation of the UBC domain, UBA domain and the Ub 
moiety coordinated by the UBA domain. Ko et al.130 report structures of Ube2K in complex 
with monoubiquitin or a mutant Ub (UBB+1), which has been implicated in the regulation of 
amyloid-β neurotoxicity, and also display the same general topology of UBC domain, UBA 
domain and Ubdist (PDB: 3K9P and 3K9O). Across multiple studies equivalent binding 
interfaces between Ub and UBA domain of Ube2K were reported130,131,124 (PDB: 
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Figure 11: Compilation of existing structural information on Ubc1 and Ube2K. (A) The interaction interface 
between UbA (teal) and the UBC domain (green) of Ube2K (PDB: 5DFL) was replicated according to HADDOCK 
modelling by Middleton and Day.124 (B) Selected atoms in the complex of UbA and Ube2K are highlighted as 
spheres: C in carboxy group of UbA G76 (red), S in Ube2K active site Cys (yellow), N in UbA ε –amino groups of 
Lys-residues and in the backbone of M1 (blue). (C) An NMR ensemble of Ubc1 (PDB: 1TTE) was superimposed 
through alignment of the UBC domain on the model from A. The linker region connecting the UBA domain (red, 
transparent) and the UBC domain shows high flexibility.105 (D) The structure of Ube2K with Ub bound to the UBA 
domain (PDB: 6IF1) was superimposed on the model from A. L71 in the C-terminus of Ubdist is represented as 
white sphere. (E) Distances were measured in the model complex for different known conformations.  
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6IF1, 3K9P, 5DFL), which are consistent with structures of other UBA domains in complex 
with Ub as shown for UBR5 (PDB: 2QHO)132 and Dsk2 (PDB: 4UN2)133. Superimposition of 
Ube2K, which binds Ub (Ubdist) through the UBA domain (PDB:6IF1), with the Ube2K/UbA 
complex reveals that Ubdist resides in close proximity to UbA (Figure 11D). This data supports 
a model in which the UBA domain associates with a distal Ub moiety relative to the immediate 
acceptor Ub. 
To evaluate whether Ubdist and UbA are sufficiently close to be covalently linked, I assessed 
distances between Ubdist and UbA in different known protein conformations using Chimera 1.13 
(Figure 11E). For a covalent bond to be possible in the model complex the carboxy C-atom in 
G76 of Ubdist needs to be located within 1.32 Å of an N-atom in a lysine side chain or the 
backbone amino group of M1 in UbA. Because Ub has a highly flexible C-terminus between 
L71 and G76 (Figure 2B), I measured the distance between the carboxy C-atoms (CC) of L71 
and G76 in an NMR ensemble of 116 structures (PDB: 2K39). The average distance was 
12.0 ± 2.3 Å with a maximal distance of 16.3 Å. Thus, a putative attachment site in UbA should 
be no further than 17.6 Å away from L71-CC. The distance between L71-CC and Nε-atoms in 
UbA was measured for the 25 most frequent Lys-rotamers.134 The ε-amino group in K63 
(K63-Nε) was found to be the closest attachment site in UbA with a minimal distance of 14.4 Å, 
which is compatible with a covalent link between Ubdist and UbA. The next closest attachment 
was found to be M1-Nα, which was at a distance of 23.1 Å from L71-CC. All other possible 
attachment sites were at least 26.9 Å away. In conclusion, I propose based on previously 
reported structural information that the UBA domain associates with a Ub moiety in a distal 
position relative to the immediate acceptor Ub. Moreover, the presented structural model 
implies that association of the UBA domain with the UBC domain creates a binding interface 
suitable for interaction with two adjacent Ub moieties in a K63 chain. 
2.2.1.2 Purification of Ubc1 cross-linked to K63-linked diubiquitin for crystallisation 
To explore the putative association of Ubc1 with K63 chains, which I also confirmed in in vitro 
binding experiments and activity assays (sections 2.2.2 and 2.2.3), I aimed to investigate a 
complex of Ubc1 and 63Ub2 by X-ray crystallography. To this end, a purification strategy was 
devised, in which the active site of Ubc1 should be cross-linked through ethane-dithiol (EDT) 
to acceptor Ub with a K48C substitution. This should be achieved through sequential 
transthiolation reactions (Figure 12A), which exploit activation of sulfhydryl groups with 
2,2-dithiodipyridine (AT2). By using EDT to connect the two molecules, a product (Figure 12B)  
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Figure 12: Purification strategy to capture Ubc1 with pseudo donor Ub in complex with acceptor 63Ub2. 
(A) Cross-linking of two proteins through sequential use of 2,2-dithiodipyridine (AT2) and ethane-dithiol (EDT). 
(B) Cross-linking product of Ubc1-Ub and 63Ub2 with Ub(K48C) at the proximal position. (C) Transition state of 
a nucleophilic attack by the ε-amino group of K48 in Ub on the Ubc1~Ub thioester. Concept adapted from 
Streich Jr and Lima.135 (D) Purification strategy for a tag-free complex of autoubiquitinated Ubc1 cross-linked 
through EDT to 63Ub2 (Ubc1-Ub-X-63Ub2).  
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should be formed, which contains the exact same number of atoms between Cα of C88 in Ubc1 
and Cα of Ub C48 (originally K48) as the native transition state (Figure 12C). The difference in 
distance should be no more than 1-2 Å.135 This approach emulates a strategy, which has 
previously been reported for the investigation of the ubiquitin like protein SUMO in the context 
of its cognate E2 enzyme Ubc9.135 Moreover, Ubc1 should be autoubiquitinated at K93 (Ubc1-
Ub) to mimic an active Ubc1~Ub thioester. 
The final purification strategy, which aimed to produce a complex completely free of affinity-
tags, consisted of three main steps (Figure 12D). (1) 63Ub2 was enzymatically assembled from 
Ub(K48C, G75*) and Ub(K63R) in a reaction with Ubc13 and Uev1a. Ub(K48C, G75*) could 
serve only as acceptor in the reaction because it lacks C-terminal glycine residues, which are 
required for activation by E1 and E2 enzymes. Ub(K63R) blocks extension of K63 chains 
beyond diubiquitin, enhancing the yield. 63Ub2 was purified from the reaction mix using ion 
exchange chromatography (IEX) and size exclusion chromatography (SEC) as described 
elsewhere.136 (2) Ubc1 was autoubiquitinated with a fusion of hUb(K48R) and n-terminally 
6xHis tagged Smt3. Autoubiquitinated Ubc1 was isolated from the reaction mix by metal 
affinity chromatography (Figure 13A). Senp2 protease was used to separate Smt3 from 
autoubiquitinated Ubc1. The protease and cleavage products were removed by a second IMAC 
step (“His-Passback”). Ubc1-Ub was further purified from the flow-through by SEC (Figure 
13B). (3) 63Ub2 and Ubc1-Ub were cross-linked by sequentially adding 63Ub2 to AT2, EDT and 
then again AT2, before mixing it with Ubc1-Ub (Figure 13C). Between each step excess cross-
linking reagents were removed with desalting columns. The final complex (Ubc1-Ub-X-63Ub2) 
was purified from the reaction mix through SEC. Ubc1-Ub-X-63Ub2 was analysed by SDS-
PAGE (Figure 13D) and mass-spectrometry to confirm integration of EDT (data not shown). 
The stability of the complex was tested by incubation at 4°C or at RT for 16 days respectively. 
Untreated sample and sample incubated with 50 mM DTT for 5 min on ice were analysed by 
SDS-PAGE and coomassie staining (Figure 13E). No degradation over time was observed. 
Therefore, Ubc1-Ub-X-63Ub2 was subsequently employed in crystal trials as outlined in section 
4.2.5.1. 
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Figure 13: Purification of Ubc1-Ub-X-63Ub2. Samples taken during purification were analysed by SDS-PAGE 
and Coomassie staining. (A) Metal affinity purification of Ubc1 autoubiquitinated with 6xHis-Smt3-hUb. 
Ubc1-Ub was obtained after Senp2 digest and His-passback. (B) Elution profile and corresponding samples of size 
exclusion chromatography for purification of Ubc1-Ub using Superdex HiLoad 16/60 75 pg. (C) Chemical cross-
linking of 63Ub2 to Ubc1-Ub. (D) Reaction product from C after purification by SEC. Side fractions with impurities 
were subjected to a second (F2) and third (F3) SEC run. For crystallisation experiments protein from F1 was used. 
(E) The stability of the complex was tested by incubation at 4°C or at RT for 16 days respectively. Samples were 
taken at indicated time points and flash frozen. Untreated samples and samples incubated with 50 mM DTT for 5 
min on ice were analysed. 
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2.2.1.3 Crystal structure of Ubc1-Ub cross-linked to K63-linked diubiquitin 
Crystallisation and data collection was performed according to section 4.2.5. In brief, crystals 
were grown for two weeks at 10°C in 6.5% PEG 6000, 100 mM MgCl2 and 100 mM 
HEPES pH 7.0 and diffracted to 3.2 Å at Swiss Light Source. Together with Dr. Jérôme 
Basquin (MPIB, Martinsried) and Dr. Rajan Prabu (MPIB, Martinsried), I was able to solve the 
structure by molecular replacement. The final model had an Rwork of 20.2% and Rfree of 23.2%. 
Data collection and refinement statistics (Table 1), as well as exemplary images of the electron 
density map (Figure 30), are shown in the supplementary data (pp. 91-92) 
The complex arrangement observed in the asymmetric unit is displayed in Figure 14A. The 
distal Ub moiety in the acceptor diubiquitin (Figure 14B, pink) is missing from the structure 
(Figure 14C). Despite indications of another Ub monomer in the electron density map and 
sufficient space to accommodate this protein, any attempts to model Ub at the respective 
position failed. High flexibility of the distal moiety in 63Ub2 and a lack of coordination to other 
domains within the complex might be reasons for this. UbD and Ubc1 adopted an open 
conformation within the complex (Figure 14A, right panel). Examination of crystal packing 
revealed that the UBA domain made extensive contacts with UbD from a symmetry related 
complex (Figure 14D). Accordingly, superimposition of the Ube2K/UbA model, outlined in 
section 2.2.1.1, on the obtained structure (Figure 14A, grey) showed that the UBA domain was 
differently positioned relative to the UBC domain (Figure 14B*). The symmetry related UbD 
formed a binding interface with the UBA domain (Figure 14E) which closely resembles 
previously reported data for this family of UBDs (Figure 15A). While UBA domains share little 
sequence similarity across the family, they share a common fold, in which three α-helices with 
approximately ten amino acids form a bundle. The helices are labelled α1, α2 and α3 from N- 
to C-terminus. Helix α1 and α3 comprise a hydrophobic binding interface, which associates 
with the hydrophobic patch in Ub clustering around I44. Strinkingly, the side chain of R42 in  
Ub may form hydrogen bonds with polar side chains of helix α3 in each respective UBA domain 
(E211 in Ubc1). Other components of the Ubc1-Ub-X-63Ub2 complex do not contribute to the 
association of the UBA domain with UbD. Thus, binding of UbD by the UBA domain does not 
appear to have unique properties as compared to binding monoubiquitin in solution. This inter-
complex contact or Ubc1 oligomerisation have no obvious implication for Ubc1 activity and 
might occur as a result of crystal packing. 
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Figure 14: Structure of Ubc1-Ub in complex with 63Ub2 was determined by X-ray crystallography. 
(A) Structure of Ubc1-Ub-X-63Ub2. The model for Ube2k/UbA complex (Figure 11B) was superimposed on the 
structure and is shown in grey. (B) Cartoon of structural model for Ubc1 based on in silico modelling (Figure 11D). 
Asterisk (*) indicates UBC/UBA interface. (C) Cartoon of the observed Ubc1-Ub-X-63Ub2 structure in A. (D) 
Cartoon of crystal contacts, which were formed between the UBA domain and UbD from a symmetry related 
complex. (E) Structure of Ubc1-Ub-X-63Ub2 with UbD from symmetry related complex. (F) Hypothetical model of 
Ubc1-Ub interacting with 63Ub2. A structure of Ubc1 with donor Ub (magenta) in closed conformation (PDB: 
1FXT) was superimposed on the UBC domain. The experimentally observed UBA/Ub complex is shown in grey. 
Additionally, the interface between UBA domain (red) and Ub (yellow) was aligned with the position of the UBA 
domain in crystal structures of Ube2K (section 2.2.1.1). An alternative conformation of the C-terminus in Ubdist 
(yellow) was integrated from an NMR ensemble of Ub (PDB: 2K39 , Figure 2B) 
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The binding interface between the immediate acceptor Ub and the UBC domain (Figure 15B) 
closely resembled the proposed model for Ube2K (Figure 11A,B), which was originally 
obtained through HADDOCK modelling. Consistent with the model, residues around the active 
site in Ubc1 associated with a loop in UbA, which includes D58, N60 and the catalytically 
important Y59124. UbA D58 was sufficiently close for hydrogen bonds to S81 and T84 in Ubc1 
corresponding to S85 and T88 in Ube2K respectively. Moreover, UbA N60 could adopt 
hydrogen bonds to S82 and D123 in Ubc1 corresponding to S86 and D127 in Ube2K 
respectively. The amino acids involved in this binding interface are conserved between Ubc1 
and Ube2K and superimposition of the model with the structure showed analogous topology 
(Figure 15C). 
Further analysis of symmetry molecules showed that UbD was restricted from adopting a closed 
conformation by crystal packing (Figure 15D-F). Symmetry related UbD (Figure 15F, grey) was 
located in proximity to the crossover helix α2 of Ubc1 (Figure 15F, green). Superimposition of 
the thioester Ubc1~Ub in closed conformation (PDB: 1FXT) on the complex, showed that the 
symmetry related UbD occupies the same space as UbD from 1FXT (Figure 15F, magenta). C-
terminal residues of UbD from 1FXT align with Ub attached to K93 in Ubc1. Thus, in principle 
Ub attached to K93 in Ubc1 should be able to associate with the crossover helix α2. The position 
of UbA in the complex is compatible with open and closed conformations of Ubc1 with UbD 
(Figure 15F). 
The overall complex architecture observed for Ubc1-Ub-X-63Ub2 does not provide an obvious 
implication for Ubc1 activity or the function of the UBA domain. The value of the structural 
data lies in the confirmation of the binding interfaces between UbA and the UBC domain as 
well as between the UBA domain and the associated Ub molecule. These interfaces were the 
basis for the structural model presented in section 2.2.1.1. However, the postulated position of 
the UBA domain relative to the UBC domain could not be observed. The distance between L71-
CC in Ub associated with the UBA domain and UbA K63-Nε is 23.8 Å. To accommodate the 
model of Ube2K/63Ub2 complex for Ubc1, intramolecular motions between the UBA domain 
and the UBC domain in Ubc1 would have to reduce this distance by 7.5 Å (Figure 14F). This 
could be achieved by a rigid body rotation of approximately 30° of the UBA domain with 
associated Ub around the UBC domain (Figure 14F). Both positions of the UBA/Ub complex 
are compatible with UbD in closed conformation with the UBC domain (Figure 14F).  
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Figure 15: Interaction interfaces in the crystal structure of Ubc1-Ub in complex with 63Ub2. (A) 
Superimposition of the interface between UBA domain and UbD from Ubc1-Ub-X-63Ub2 on UBA/Ub interfaces 
of Ube2K, Dsk2 and UBR5. Selected side chains are shown in stick representation. (B) The interaction interface 
between the UBC domain and UbA from Ubc1-Ub-X-63Ub2. (C) The interface of Ube2K/UbA (grey) inferred from 
HADDOCK modelling (Figure 11A) was superimposed on B. (D) Cartoon of crystal contacts to UbD in 
Ubc1-Ub-X-63Ub2 . UbD associates with the UBA domain from one symmetry related complex and with the UBC 
domain of another symmetry related complex. (E) Cartoon of a structure of the Ubc1 UBC domain with Ub in 
closed conformation137 (PDB: 1FXT). (F) The structure depicted in E (magenta) was superimposed on Ubc1-Ub-
X-63Ub2 through alignment of the UBC domain. Symmetry related molecules are shown in transparent grey. I44 
in UbD is highlighted by an arrow to indicate the binding interface with the UBA domain. Symmetry related UbD 
from the adjacent Ubc1 complex clashes with UbD from 1FXT.   
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2.2.2 Characterisation of Ub binding by Ubc1 
2.2.2.1 Ubc1 preferentially binds to K63 chains over K48 chains via its UBA domain in 
in vitro binding experiments 
To investigate the putative preference for K63 chains over K48 chains inferred from structural 
modelling, I aimed to assess binding preference of Ubc1 towards differently linked Ub chains. 
To this end, I performed qualitative in vitro binding experiments. Preliminary experiments 
suffered from a limited dynamic range in Ub detection based on western blotting and antibody 
binding (not shown). Therefore, I devised a fluorescence based in vitro binding assay. K63 
chains or K48 chains were assembled from wild type Ub and Ub(S20C,G76-6xHis), which was 
the target for fluorescent labelling. A mix of Ub chains with different lengths was generated, in 
which each Ub chain contains a single fluorophore facilitating quantitative detection. Binding 
of these chains to different GST-fusion proteins immobilised on glutathione sepharose was 
analysed (Figure 16A). The UBA domain of Dsk2 (aa241-374) served as a positive control, as 
it was previously reported to bind different Ub chains relatively unspecifically.81 GST expressed 
from an empty pGex6p1-vector was used as negative control. Ubc1 expression vectors 
harboured either the full length enzyme (GST-Ubc1), only the catalytic core domain (GST-
UBC, aa1-150), the UBA domain (GST-UBA, aa151-215) or a Ubc1 variant with amino acid 
substitutions, which were previously reported to disrupt Ub binding129 (GST-LRV, aa179-
181QGF to LRV). Protein amounts were adjusted based on SDS-PAGE and Coomassie staining 
(Figure 16C). After the immobilised fusion proteins were incubated with the respective mix of 
fluorescently labelled Ub chains, supernatant and resin were separated. Fluorescent Ub chains 
associated with resin (“bead bound”) or remaining in the supernatant were analysed by SDS-
PAGE and fluorescence scan (Figure 16A). Total fluorescence in each sample was quantified 
and fluorescence signal from bead bound Ub chains over total fluorescence in both fractions 
was normalised to GST-Dsk2 for each construct (Figure 16B). Full length Ubc1 and the Ubc1 
UBA domain interacted with K63 chains more tightly than with K48 chains. Weak or unspecific 
binding of Ub chains was observed for the GST-tag alone as well as for the UBC domain and 
Ubc1-LRV. The UBC domain and Ubc1-LRV were found to be poorly expressed in S. cerevisiae 
(data not shown). Therefore, I created and tested different Ubc1 variants, among which only 
Ubc1 E211A, E212A (Ubc1-EEAA) was stably expressed in S. cerevisiae (not shown) and 
impaired in binding to Ub (Figure 16D). These findings corroborate the proposed structural 
model as they show that Ubc1, via its UBA domain, interacts preferentially with K63 chains 
over K48 chains, which are its enzymatic product.  
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Figure 16: The UBA domain of Ubc1 mediates preferential binding to K63 chains over K48 chains. (A) 
Fluorescence scan of in vitro binding experiment with fluorescently labelled K48 chains and K63 chains. (B) Total 
fluorescence per lane in A was quantified. Fluorescence in bead bound fraction over total fluorescence in both 
fractions was normalised to Dsk2-UBA. (C) Input controls of immobilised GST fusion proteins for binding 
experiments were analysed by SDS-PAGE and Coomassie staining. (D) The binding experiment from A was 
repeated to assess the binding of K63 chains by Ubc1 with amino acid substitutions E211A and E212A (GST-Ubc1 
EEAA). First panel shows input controls as described in C.  
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2.2.2.2 Assessment of binding affinity between Ubc1 and differently linked diubiquitin 
probes by microscale thermophoresis (MST) 
I carried out microscale thermophoresis experiments in the biophysical core facility of the Max 
Planck Institute for Biochemistry (Martinsried) with Dr. Stefan Übel, who supervised method 
development. 
 
Figure 17: Microscale Thermophoresis experiments with Ubc1 and 11Ub2, 48Ub2 and 63Ub2 respectively. 
(A) Relative fluorescence is traced over time. Upon excitation (t0) Ub chains diffuse out of the induced temperature 
gradient and fluorescence intensity decreases until heating is stopped (15s). Subsequently fluorescence is 
recovered through back diffusion. (B) The different Ub chains in (A) were titrated with Ubc1 and relative 
fluorescence was integrated from t(-1s) to t(0s) and from t(14s) to t(15s). The difference between these time points 
(ΔFluo.) decreases with increasing concentration of Ubc1. ΔFluo. was normalised to buffer controls, plotted for 
different concentrations of Ubc1and approximated with a sigmoidal function to obtain estimated(*) dissociation 
constants. 
To validate the findings from qualitative binding experiments, I aimed to measure binding 
affinities between full-length Ubc1 and differently linked diubiquitin probes by microscale 
thermophoresis (MST). MST relies on observation of a fluorescently labelled ligand and its 
directed movement in a microscopic temperature gradient (thermophoresis), which can be 
altered by inter-molecular binding events. Therefore, I created fluorescently labelled 48Ub2 and 
63Ub2 with a proximal Ub harbouring a C-terminal cysteine residue and a 6xHis-tag. 
Dr. Edmund Watson (MPIB, Martinsried) kindly provided 11Ub2 created from the same Ub 
monomers. I tested thermophoretic mobility of diubiquitin probes (Ub2*) in different buffers 
and conditions. Ultimately, thermophoresis of 200 nM Ub2* was measured in 200 mM NaCl 
and 50 mM MES (pH 6.2) in polymer coated capillaries (Figure 17A). A response rate was 
defined as change in fluorescence between the time frames t0 (-1s to 0s) and t1 (14s to 15s). 
Upon addition of Ubc1 into the samples the response rate of Ub2* decreased indicating reduced 
thermophoretic mobility due to complex formation. The change in response rate was quantified 
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 for different concentrations of Ubc1 (Figure 17B). At the maximal concentration of 2.3 mM 
(56 mg/ml) Ubc1 the change of response was still increasing. Extrapolation of the data suggests 
that the inflection point for 63Ub2 was reached. Exact determination of Kd values requires signal 
saturation as the Kd value is extracted from the inflection point of a sigmoidal curve 
approximation. Previous attempts to quantify binding affinities between UBA domains and Ub 
through comparable biophysical methods (e.g. surface plasmon resonance) have encountered 
similar problems.132 Based on extrapolation of the recorded data set, Kd values were estimated 
to several hundred micromolar for 63Ub2 and to up to 1 mM for binding to 11Ub2 and 48Ub2. 
Ubc1 showed generally low binding affinity for Ub with a weak preference for 63Ub2. 
2.2.2.3 Binding of individual moieties in K48 and K63 diubiquitin by the UBA domain 
was assessed by NMR titration experiments 
NMR titration experiments shown in this section were performed by Dr. Andreas Kniss from 
the laboratory of Prof. Dr. Volker Dötsch (Goethe University, Frankfurt).  
We showed that the CUE domain preferentially binds to K48 chains through coordination with 
additional amino acids in the C-terminus of the distal moiety in 48Ub2. The Rad23A UBA 
domain employs a similar mechanism, which relies on binding two adjacent moieties in 
K48 chains simultaneously. We hypothesised that Ubc1 might preferentially associate with K63 
chains in a similar way. Thus, we performed NMR titration experiments of the Ubc1 UBA 
domain with 15N labelled diubiquitin probes (Figure 18), as described in section 2.1.1. The 
strongest chemical shift perturbations (CSPs) were observed for amino acids within the 
hydrophobic patch (I44, L8, G47, V70, R42, H68). Interestingly, several residues in the C-
terminus of Ub were also implicated in binding (L71, R72). A prominent difference to binding 
of Ub by the CUE domain is a strong CSP of K48 in Ub, which appears to contribute to binding 
by the UBA domain. No striking difference in CSPs could be observed between individual 
moieties of 63Ub2 (Figure 18A,B). In contrast, CSPs in the proximal moiety of 48Ub2 were 
generally lower than in the distal moiety, which was most prominent for K48 (Figure 18C,D). 
Previous studies report a Kd value of 228 ± 68 µM for binding of monoubiquitin by the Ubc1 
UBA domain as assessed by NMR experiments.105 To determine dissociation constants between 
individual Ub moieties within the diubiquitin probes and the UBA domain, the CSP of I44 was 
measured for increasing concentrations of UBA domain (Figure 18E). Based on this titration 
experiment dissociation constants were calculated (Figure 18F). Kd values of 193 ± 13 µM and 
188 ± 20 µM were determined for the distal and proximal moiety in 63Ub2 respectively, whereas 
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Figure 18: Interaction of individual ubiquitin moieties in 48Ub2 and 63Ub2 with the UBA domain of Ubc1. 
15N labelled diubiquitin probes as introduced in section 2.1.1 were titrated with the UBA domain up to molar ratio 
of 8:1 (UBA : Ub2). The spectra were recorded for 15N labelling of (A) distal moiety in 63Ub2, (B) proximal moiety 
in 63Ub2, (C) distal moiety in 48Ub2 and (D) proximal moiety in 48Ub2. (E) CSP of I44 for individual moieties was 
plotted over UBA domain concentration to calculate binding affinities as in Figure 6E and F. (F) Kd values obtained 
from E. 
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Kd values of 259 ± 58 µM and 382 ± 98 µM were determined for the distal and proximal moiety 
in 48Ub2, respectively. It appears ubiquitinated K48 in Ub interferes with the association of the 
Ubc1 UBA domain. In summary, no site specific interaction with K63 chains could be observed 
for the UBA domain of Ubc1. However, impaired binding of Ubc1 to its enzymatic product 
(K48 chains) is in agreement with the proposed structural model. 
 
2.2.3 In vitro ubiquitination activity of Ubc1 
2.2.3.1 Ubc1 acts cooperatively with Ubc4 and assembles K48-linked polyubiquitin 
As a starting point for the investigation of Ubc1 activity through in vitro ubiquitination 
experiments, I aimed to test the ability of Ubc1 to assemble K48 chains processively under 
conditions previously used to study Ubc7.84 In the presence of Hrd1 RING domain and its 
activating co-factor Cue1, Ubc7 forms a distinct ladder of short Ub chains with increasing 
length as well as high molecular weight polyubiquitin (Figure 19A). Previous studies showed 
that Ubc1 is also activated by the E3 ligase Hrd1 in the context of ER associated protein 
degradation (ERAD).21 However, unlike for Ubc7, formation of a distinct Ub ladder indicative 
of sequential de novo chain synthesis could not be observed in reactions with Ubc1 (Figure 
19B). Instead, slow formation of high molecular weight Ub species and a prominent signal 
below the 30 kDa marker band indicative of autoubiquitination were observed. (Figure 19B). 
The binding deficient Ubc1 variant Ubc1-LRV (section 2.2.2.1) showed a similar product 
pattern as wild type Ubc1 (Figure 19A, right panel). Ubc1 was previously reported to be 
cooperatively active with the E2 enzyme Ubc4.110 Thus, I included Ubc4 into the in vitro 
ubiquitination assays. The pattern of polyubiquitin bands generated by Ubc7/Cue1 was not 
affected by the presence of Ubc4 in the reaction (Figure 19A). Employing Ubc1 together with 
Ubc4 yielded more rapid formation of high molecular weight products than for Ubc1 or Ubc4 
alone suggesting cooperative activity (Figure 19B). To assess consecutiveness in the 
cooperative activity of Ubc1 and Ubc4, I performed sequential in vitro ubiquitination reactions 
(Figure 19C). GST-tagged Hrd1-RING was employed in an in vitro ubiquitination reaction with 
either Ubc1 or Ubc4, subsequently removed from the reaction using glutathione sepharose and 
employed in a second reaction with the other E2 enzyme. Incubation with Ubc4 first and with 
Ubc1 second resulted in a distinct pattern of reaction products compared to reactions with only 
the individual E2 enzymes (Figure 19B). This sequence of reactions resulted in a shift towards 
higher molecular weight Ub species. It appears Ubc1 extends Ub modifications generated by 
Ubc4 in presence of the Hrd1-RING domain. To investigate what kind of Ub chains were 
2. Results 
43 
formed in the in vitro ubiquitination reactions, samples from reactions with Ubc1 and Ubc4 
were submitted for analysis by targeted proteomics as described elsewhere138 (Figure 19E). In 
short, the reaction mix was subjected to tryptic digest and isotope labelled marker peptides for 
different linkage types were added. Subsequent analyses by single reaction monitoring showed 
the abundance of differently linked Ub chains. In line with previous reports, Ubc1 exclusively 
assembled K48 chains. Ubc4 generated small amounts of K11, K48 and K63 chains. In 
summary, I found Ubc1 to exclusively assemble K48 chains, albeit with lower processivity than 
Ubc7/Cue1, and to extend ubiquitin modifications generated by Ubc4.  
The performed experiments did not allow for distinction between the formation of free ubiquitin 
chains and the modification of E2 or E3 enzyme with multiple monoubiquitins or ubiquitin 
chains. To assess the ability of Ubc1 to extend preformed Ub chains in the absence of Hrd1 
RING domain and Ubc4, I aimed to devise single turnover ubiquitination experiments, in which 
a single product should be formed allowing determination of kinetic rates. To this end, I 
performed in vitro ubiquitination reactions with a 10:1 molar ratio of K48-linked tetraubiquitin 
(48x3Ub4), which was C-terminally capped with a 6xHis-tag, and fluorescent Ub as donor 
(Figure 19D). To discriminate between modification of the designated acceptor Ub and other 
reaction products, I used Talon metal affinity resin to remove His-tagged proteins from the 
reaction mix. Samples were analysed by SDS-PAGE and subsequent fluorescence scan, as well 
as Coomassie staining. Coomassie staining revealed the efficient removal of the 6xHis-tagged 
Ub chains (Figure 19D, bottom panel). Reactions with wild type Ubc1 and the Ubc1 UBC 
domain yielded multiple fluorescence signals in the supernatant corresponding to 
autoubiquitination. These signals were not observed for Ubc1 and the UBC domain with K93R 
amino acid substitution. The formation of pentaubiquitin as product of the elongation reaction 
was not affected by the introduction of K93R. However, less product was formed in presence 
of the UBC domain as compared to full length Ubc1. By employing Ubc1(K93R), I was able 
to identify reaction conditions suitable to investigate the elongation of different acceptor Ub 
molecules by Ubc1.  
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Figure 19: Ubc1 displays cooperative activity with Ubc4, assembles K48 linked chains and autoubiquitinates 
through K93. (A) In vitro ubiquitination experiments were performed with Ubc7/Cue1 and Ubc4 in the presence 
of Hrd1 RING-domain. Samples were taken at indicated time points and analysed by SDS-PAGE and western 
blotting using a primary antibody against Ub. (B) Reactions as in A with Ubc1 and Ubc4 (without Cue1). (C) In 
vitro ubiquitination reactions as in B were performed sequentially. Numbers in the table indicate presence of the 
respective component during the first or second reaction. C399S amino acid substitution in Hrd1 renders RING 
domain dysfunctional. (D) Single turnover ubiquitination reactions were performed with fluorescent 
monoubiquitin and K48-linked tetraubiquitin with a C-terminal 6xHis tag as acceptor over night. Acceptor Ub was 
separated from the reaction mix through metal affinity chromatography. Subsequent coomassie staining (E) Mass 
spectrometric quantification of polyubiquitin linkage types formed in in vitro ubiquitination reactions as in B with 
Ubc1 and Ubc4. The analysis was performed by Dr. Patrick Beaudette from the MS core facility at MDC (Berlin) 
under the lead of Dr. Gunnar Dittmar.  
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2.2.3.2 Ubc1 selectively assembles K48/K63 branched chains 
To test the model of Ubc1 interaction with K63 chains, I aimed to quantitatively assess the 
ability of Ubc1(K93R) to extend different preformed Ub chains. Therefore, I performed kinetic 
analyses of single turnover ubiquitination experiments, which were introduced in section 
2.2.3.1. Different C-terminally capped Ub probes as acceptors and fluorescently labelled 
monoubiquitin as donor were employed at a 10:1 molar ratio in reactions with Ubc1(K93R). 
Under these conditions only a single product was formed, which was analysed by SDS-PAGE 
and fluorescence scans (Figure 20A). I quantified product fluorescence over total fluorescence 
per lane and plotted this ratio over time. The resulting curves revealed a linear increase of 
fluorescence over the first 20 min for all probes (Figure 20B). Initial reaction rates were 
determined as the slope of the linear increase in fluorescence intensity over this time period. 
Exemplary fluorescence scans for all probes are shown in the supplementary data (Figure 31, 
pp. 93). Initial rates in presence of full-length Ubc1 were approximately 16 times faster for 
63Ub2 than for 48Ub2 or monoubiquitin (Figure 20C). Reactions with only the UBC domain – 
i.e. Ubc1 lacking its UBA domain – showed ~20% reduced reaction rates for 48Ub2 and 
monoubiquitin as acceptors, whereas this reduction was 85% for 63Ub2 (Figure 20C). In 
summary, Ubc1 preferentially targets 63Ub2 in a UBA domain dependent manner. 
To investigate this preferential turnover of 63Ub2, I performed mutational analysis. I introduced 
Ub(K48R), which blocks the acceptor site for Ubc1, or Ub(R42A), which interferes with 
binding of the UBA domain, into different positions of 63Ub2 and performed single turnover 
ubiquitination experiments with Ubc1(K93R) (Figure 20D). Blocking the proximal acceptor 
site impaired Ubc1 activity strongly, while blocking the distal acceptor site had only a minor 
impact. Conversely, introducing R42A into the proximal Ub moiety had no effect on Ubc1 
activity, whereas R42A in the distal moiety disrupted the rapid turnover of 63Ub2(K48R). The 
position specific effects of the amino acids substitutions support a mechanism, in which the 
Ubc1 UBA domain binds to the distal moiety of 63Ub2 to align the UBC domain with the 
proximal moiety in line with the structural model proposed in section 2.2.1.1. This leads to the 
formation of a K48/K63 branched Ub chain. Accordingly, the binding deficient 
Ubc1(K93R,E211A,E212A) showed reduced activity towards 63Ub2(K48R) as compared to 
Ubc1(K93R) (Figure 20F). 
To assess preference of Ubc1 towards K63 chains over other substrates, I aimed to compare 
Ubc1 activity in presence of 63Ub2 and the structurally related M1Ub2. M1 chains have been 
shown to mostly adopt open conformations similar to K63 chains.72 Moreover, M1 in Ub is  
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Figure 20: The UBA domain of Ubc1 facilitates the assembly of K48/K63 branched chains. (A) Single 
turnover ubiquitination experiments with Ubc1(K93R) were performed in presence of fluorescently labelled 
monoubiquitin and different acceptor Ub molecules at a 1:10 molar ratio. Samples were taken at indicated time 
points and analysed by SDS-PAGE and fluorescence scan. (B) Fluorescence of reaction product over total 
fluorescence per lane was plotted over time for reactions with different acceptor Ub. Data points over the first 
20 min were approximated by a linear fit to determine initial reaction rate (slope). Representative traces for 
reactions containing indicated components. (C) Experiments from B were performed in triplicate for the indicated 
acceptor Ub with either full-length Ubc1-K93R (grey) or Ubc1 UBC-K93R domain (aa1-150, yellow). Error bars 
show mean and SEM. (D) In the same set of experiments as in C, the activity of full-length Ubc1-K93R towards 
63Ub2 with the indicated amino acid substitution(s) was analysed. (E) The experiment from D was repeated with 
K63 chains and M1 chains with Ub(K48R) at the indicated positions. (F) Experiment from A was performed with 
63Ub2(K48R) in presence of Ubc1 (wt), Ubc1-E211A,E211A (EEAA) or only the UBC domain (ΔUBA). 
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located in close proximity to K63 (Figure 2D). Thus, I created different M1-linked Ub probes  
harbouring Ub(K48R) at different positions and repeated the single turnover ubiquitination 
experiments outlined in the preceding paragraphs (Figure 20E). Higher initial rates were 
observed in reactions with M1Ub2(K48R) than with M1Ub1(K48R). Evidently, the region-
selectivity of Ubc1 observed in K63 chains translates to turnover of M1 chains. However, initial 
rates for the M1-linked probes were approximately three times lower than for K63 chains. At 
this point no factor has been identified that assembles M1 chains in S. cerevisiae. Accordingly, 
I propose K63 chains as the preferential substrate of Ubc1. 
I aimed to verify my results from the single turnover ubiquitination experiments through in vitro 
ubiquitination reactions, in which formation of branched chains by Ubc1 competes with de novo 
chain synthesis (Figure 21A). I hypothesised that under conditions favourable for chain 
assembly by Ubc1 (“de novo”), K63 chains could provide a scaffold for Ubc1, which induces 
processive assembly of K48 chains (“processive”). Alternatively, adjacent moieties in a K63 
chain could enable Ubc1 to rapidly form multiple branching points. First, I identified conditions 
for in vitro ubiquitination reactions with fluorescently labelled monoubiquitin favourable for de 
novo chain synthesis by Ubc1 (lane 2) and the UBC domain (lane 4, Figure 21B). Subsequently, 
C-terminally blocked 63x3Ub4 was introduced in a 4-fold lower concentration than fluorescent 
monoubiquitin into the reaction mix (Figure 21B, right panel). At these concentrations, 63x3Ub4 
provides an equimolar concentration of acceptor sites relative to monoubiquitin. I tested the 
product pattern which resulted from modification of 63x3Ub4 by using methylated fluorescent 
monoubiquitin as a donor, which cannot be assembled into chains (“met”). In the presence of 
full length Ubc1 three prominent signals could be observed (lane 6) corresponding to one, two 
and three times modified 63x3Ub4, while the UBC domain only efficiently produced one 
modification of 63x3Ub4 (lane 8). Accordingly, Ubc1 showed a prominent shift in reaction 
products towards modified 63x3Ub4 (lane 5) over de novo chain synthesis (lane2), which was 
less pronounced for the UBC domain (lane 7 versus lane 4). The same results could be observed 
for a binding deficient Ubc1(K93R,E211A,E212A) variant (Figure 21C). These findings imply 
that Ubc1 is proficient in rapidly introducing multiple K48/K63 branching points. 
To investigate the conservation of this reaction mechanism among species, I performed single 
turnover ubiquitination experiments with the Ubc1 orthologues from C. elegans (ubc-20) and 
homo sapiens (Ube2K). Ubc-20 and Ube2K showed preference towards the proximal moiety 
in 63Ub2 akin to Ubc1 (Figure 21D).  
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Figure 21: Formation of K48/K63 branched chains by Ubc1 outpaces de novo chain synthesis and is 
conserved among species. (A) Schematic representation of ubiquitination reactions in B and C and their putative 
products. (B) In vitro ubiquitination reactions with Ubc1(K93R) were performed under conditions favorable for 
free chain synthesis through fluorescently labelled monoubiquitin (left panel) in absence or presence (right panel) 
of C-terminally capped 63x3Ub4 in a 4:1 molar ratio. Fluorescence scan of PAGE-gels. (C) Experiment from B, 
right panel, was repeated with Ubc1-wt (K93R) and Ubc1-EA (K93R,E211A,E212A). (D) The Ubc1 orthologues 
ubc-20 from C. elegans and the human Ube2K were expressed in E. Coli, purified and used for single turnover 
reactions with the indicated Ub probes as in Figure 20.  
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2.2.3.3 Ubc1 mutants containing exogenous Ub binding domains are impaired in 
assembling K48/K63 branched chains 
My results show that Ubc1 is dependent on its UBA domain for efficient assembly of K48/K63 
branched chains. I aimed to test whether this activity could be restored to the catalytic core 
domain of Ubc1 by linking it to other Ub binding domains which also interact with the 
hydrophobic patch in Ub. To this end, I devised expression plasmids for the Ubc1 UBC domain 
(aa1-150) linked through different linkers harbouring multiple GS repeats of either 2, 6 or 12 
amino acids length to either the CUE domain of Cue1 or the UBA domain of Dsk2 (Figure 
22A). The activity of the chimeric enzymes towards different Ub probes was tested in single 
turnover ubiquitination assays as described previously (Figure 22B). Although the variants 
slightly differed in activity towards different acceptor probes, the activity of wild type Ubc1 
towards the proximal moiety in 63Ub2, eclipsed the efficiency of all other reactions. These 
results suggest that activation of Ubc1 by its UBA domain is dependent on unique features 
within this domain. 
 
Figure 22: Single turnover ubiquitination reactions with Ubc1 variants containing Ub binding domains from 
either Cue1 or Dsk2. (A) Fusion proteins with the catalytic core domain of Ubc1 (aa1-150), a linker region with 
one to six repeats of GS and either the CUE domain of Cue1 (aa241-373) or the UBA domain of Dsk2 (aa24-203) 
were created. (B) Single turnover ubiquitination reactions were performed as in Figure 20. Reaction endpoints 
were analysed by SDS-PAGE and fluorescence scan. Asterisk indicates free dye contaminant from fluorescently 
labelled Ub. 
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2.2.4 The enzymatic product of Ubc1 – K48/K63 branched ubiquitin chains 
2.2.4.1 Detection of branched chains in vitro and in vivo 
Having discovered the preference of Ubc1 to assemble K48/K63 branched chains, I aimed to 
interrogate the existence of this little studied chain architecture in S. cerevisiae. At this point 
Ohtake et al. succeeded in detecting K48/K63 branched chains in a mammalian cell line by a 
novel mass spectrometric method.58 In collaboration with Dr. Henrik Zauber from the group of 
Prof. Dr. Matthias Selbach (MDC, Berlin), we emulated this approach. The detection method 
relies on introducing an R54A amino acid substitution into Ub and thereby removing a cleavage 
site for trypsin. Lysine residues targeted by ubiquitination are protected from the tryptic digest, 
thus resulting in lysine with two glycine residues attached (K-GG). Consequently, if K48 and 
K63 in a single Ub molecule were subjected to ubiquitination, a marker peptide for K48/K63 
branched chains ranging from L43 to R72 in Ub can be obtained after tryptic digest (Figure 
23A). To establish this detection method at our institute, I assembled a ubiquitin trimer in a one 
step in vitro reaction from C-terminally 6x-His-tagged R54A-Ub as acceptor and 
Ub(K48R,K63R) as donor by using Ubc1 and the K63-specific enzyme pair Ubc13/Uev1A 
(Figure 23B). The desired reaction product 48/63Ub3 (Figure 23C, right lane) was purified by 
metal affinity chromatography and subsequent size exclusion chromatography. The 
fragmentation properties of K48/K63 branched chains were analysed by shotgun proteomics to 
obtain a spectral library. The results reflected data from Ohtake et al.58 (data not shown). 
Having measured the fragmentation properties of this relatively large marker peptide (3.6 kDa), 
we aimed to detect its occurrence in total cell lysate of S. cerevisiae. To this end, I created two 
yeast strains which exclusively harbour N-terminally 10xHis-tagged Ub(R54A) or 
Ub(R54A,K63R). The amino acid substitution K63R should block any formation of homotypic 
or branched Ub chains though K63 and thereby serve as negative control. Total cell lysate was 
prepared from yeast grown in YPD medium and 10xHis-tagged Ub was enriched using metal-
affinity chromatography. On-bead digest with trypsin was performed with the enriched fraction 
and the eluate was analysed by Parallel Reaction Monitoring (PRM) by Dr. Henrik Zauber 
(section 4.2.4.8).139 The marker peptide for K48/K63 branches and the corresponding fragment-
ions, were detected in samples of yeast expressing Ub(R54A), but not Ub(R54A,K63R) (Figure 
23D). A dotp value140 of 0.79 revealed good correlation of the fragmentation pattern between 
the spectral library obtained from the synthesised Ub-trimer and the sample from yeast lysate 
(Figure 23E). The presence of K48/K63 branched Ub in S. cerevisiae implies that mechanisms 
to specifically assemble these Ub chains are conserved among eukaryotic organisms. 
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Figure 23: In vitro assembly of K48/K63 branched chains and their mass spectrometric detection by parallel 
reaction monitoring. (A) Amino acid sequence of Ub(R54A). “Trp” indicates trypsin cleavage sites. Modification 
of lysine residues protects them from tryptic digest (K48-GG/K63-GG). Marker peptides for homotypic chains 
and K48/K63 branched chains are indicated below the amino acid sequence. (B) Reaction scheme for preparative 
assembly of 48/63Ub3 for method development. (C) Reaction products of Ubc1 and/or Ubc13/Uev1a respectively 
were analysed by SDS-PAGE and Coomassie staining. Branched triubiquitin was used to create a spectral library 
(“synthetic reference”). (D) Identification of K48/K63 branched Ub chains by PRM from lysate of S. Cerevisiae 
expressing either Ub(R54A) or Ub(R54A,K63R). Graphs display excerpts of the chromatogram at peak retention 
time from the six most abundant fragment ions observed for Ub(R54A) and Ub(R54A,K63R) respectively. (E) 
The different coloured bars show the contribution of each fragment to the total integrated fragment ion signal of 
the marker peptide (colours as in D). The dotp value of 0.79 confirms good matching of the spectrum obtained 
from yeast lysate with Ub(R54A) with the reference spectrum. PRM measurements performed by Dr. Henrik 
Zauber. 
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2.2.4.2 Levels of K48/K63 branched chains in S. cerevisiae deleted for ubc1 
 
Figure 24: Quantification of K48/K63 branched chains from yeast lysate in presence and absence of Ubc1. 
(A) Schematic of workflow. (B) Input controls. First lane is wildtype. Analysis by SDS-PAGE and western blotting 
using the indicated primary antibodies. (C) SILAC ratios and intensities for individual marker peptide fragments 
for homotypic K63 chains (blue) and K48/K63 branched Ub (green). Different symbols indicate charges of 
fragment ions. (D) Christmas tree projections from the shotgun proteomics analysis of the SILAC experiment. 
log2-fold changes were plotted against protein intensity. Significant outliers from the log2 FC-distribution were 
detected in an abundance binned manner and are coloured in red. (E) Pairwise comparison of protein ratios from 
experiments in D. Green colour indicates proteins with a significant fold-change observed in both experiments, 
while red colour indicates proteins observed in only one experiment. 
We aimed to investigate the impact of Ubc1 on the abundance of K48/K63 branched chains. To 
do so, we combined stable isotope labelling in cell culture (SILAC) in S. cerevisiae with the 
PRM detection method outlined in the previous section (Figure 24A). First, I introduced a ubc1-
deletion into the strain expressing Ub(R54A) with N-terminal 10xHis-tag. Wild type and ubc1-
deleted yeast cells were grown in label-free SD medium or in SD medium containing 2H4-
lysine (Lys4). Input controls revealed reduced levels of high molecular weight polyubiquitin in 
ubc1 deleted cells (Figure 24B). Equal amounts of cells expressing endogenous Ubc1 grown in 
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label-free medium were mixed with cells deleted for ubc1 grown in Lys4-medium or vice versa 
to control for label dependent effects. Cell lysis was performed under denaturing conditions. 
Enrichment of 10xHis-Ub and on-bead digest for the detection of K48/K63 branched chains 
were performed as outlined in the previous section. Samples were analysed by PRM to detect 
relative differences of homotypic K63 chains and K48/K63 branched chains (Figure 24C). The 
observed peptide ratios showed reduced levels of K48/K63 branched chains in cells deleted for 
ubc1. However, conflicting results were obtained for the fold-changes of K63 chains. No 
difference was observed for cells expressing Ubc1 grown in unlabelled media as compared to 
ubc1-deleted cells grown in Lys4-labelled medium. In contrast, Lys4-labelled cells expressing 
Ubc1 contained more K63 chains than ubc1-deleted cells grown in unlabelled medium. MS1 
spectra revealed that there was no overall shift in protein ratio distribution for the individual 
samples (Figure 24D) and that samples correlated well between label swaps (Figure 24E). 
Reduced expression of multiple ribosomal proteins could be observed for ubc1-deleted strains. 
Although, this preliminary data suggests reduced levels of K48/K63 branched chains in ubc1-
deleted cells, this observation requires further validation. 
2.2.5 Huntingtin (Htt) as model substrate of Ubc1 and its homologues 
2.2.5.1 Htt in C. elegans 
 
Figure 25: Depletion of the Ubc1 orthologue ubc-20 in C. elegans induces the unfolded protein response and 
leads to aggregation of a Huntingtin derivate. (A) Fluorescence microscopy of C. elegans harbouring a reporter 
gene construct, in which YFP expression is governed by the hsp-3 (ER Hsp70) promoter. Nematodes were grown 
on E. coli expressing dsRNA against ubc-20 or the empty vector L4440 (control). Higher fluorescence signals 
indicate induction of the unfolded protein response upon depletion of ubc-20. (B) Fluorescence microscopy of C. 
elegans expressing a fusion protein of Huntingtin (aa1-513) and YFP. Depletion of ubc-20 via RNAi induces 
formation of distinct punctae (arrows) indicative of protein aggregation. 
We hypothesised that K48/K63 branched chain assembly by Ubc1 might be involved in 
fine-tuning degradation of proteins, which can be subject to autophagosomal degradation 
mediated by K63 chains as well as to proteasomal degradation mediated by K48 chains. 
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Therefore, we collaborated with Dr. Janine Kirstein (FMP, Berlin), who developed model 
systems suitable for studying disruption of proteostasis and its organismal effects in C. elegans. 
We induced RNAi mediated knockdown of the Ubc1 homologue ubc-20 in different C. elegans 
reporters. Depletion of ubc-20 had no striking effect on development or fecundity and did not 
noticeably activate heat shock response (data not shown), but caused the induction of the 
unfolded protein response as assessed by a hsp-3 reporter assay (Figure 25A). Moreover, we 
observed that ubc-20 depletion induced the aggregation of the model substrate Htt513Q15-YFP 
(Figure 25B). The propensity of Htt to form aggregates strongly correlates with increased length 
of the polyQ stretch with a critical threshold at approximately 35 amino acids.141 Thus, it was 
surprising that ubc-20 depletion led to an aggregation of a Htt construct harbouring a relatively 
short polyQ stretch of 15 amino acids. Typically, this is only caused by severe disruption of the 
cellular protein folding machinery upon, for example, knockdown of Hsp70. 
2.2.5.2 Htt in S. cerevisiae 
Because it was not feasible to create a C. elegans variant suitable for the detection of K48/K63 
branched chains, I aimed to test whether the findings from C. elegans could be transferred to 
S. cerevisiae. Htt has been previously used as a model substrate to study protein aggregation in 
S. cerevisiae.142 I obtained plasmids used by Duennwald et al. from Addgene (15576, 15577) 
and genomically integrated them into our strain background (Figure 26). These constructs are 
governed by an inducible GAL-promoter and encode for Htt Exon-1 with either Q25 or Q103 
fused to GFP and a Flag-tag. Wild type and ubc1-deleted yeast cells expressing either Htt 
construct were shifted to galactose containing media for 2h and analysed by fluorescence 
microscopy (Figure 26A). Distinct staining patterns could be observed for the different 
constructs. Htt(ExonI)25Q-GFP-Flag showed even distribution across the cytosol indicating 
good solubility (Figure 26A, left panels). In contrast, expression of Htt(ExonI)103Q-GFP-Flag 
induced the formation of distinct punctae indicating aggregate formation (Figure 26A, right 
panels). These staining patterns did not differ between wild type and ubc1-deleted cells. To 
asses protein half-life of the different Htt constructs, I performed cycloheximid chase assays 
(Figure 26B). Over the course of three hours no degradation of Htt(ExonI)25Q-GFP-Flag could 
be observed (bottom panel). Signal for Htt(ExonI)103Q-GFP-Flag decreased over time (top 
panel). However, a high molecular weight band increased in intensity over time indicating 
aggregate formation. No difference could be observed between wild type and ubc1-deleted 
cells.  
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Figure 26: Htt as model substrate in S. cerevisiae. (A) Wildtype (yTX1251) and ubc1-deleted yeast cells 
expressing different Htt constructs were analysed by fluorescence microscopy. (B) Degradation of 
Htt(ExonI)25Q-GFP-Flag or Htt(ExonI)103Q-GFP-Flag was assessed by cycloheximide chase assays. Samples 
were analysed by SDS-PAGE and western blotting with the indicated antibodies. Cdc48 was used as a loading 
control. (C) Different yeast strains expressing Htt(ExonI)25Q-GFP-Flag were grown in galactose containing 
medium over night. Total cell lysate was prepared and analysed as in B. (D) In a pilot experiment, intensities of 
different GFP marker peptides were measured by shotgun proteomics in samples obtained by Flag affinity 
purification from yeast lysate. Wild type (wt) or ubc1-deleted yeast cells (Δubc1) expressing 
Htt(ExonI)25Q-GFP-Flag or untransformed cells (control) were compared. (E) Samples obtained in D were also 
analysed by targeted proteomics (PRM) for actin (red), K48 chains (blue), total Ub (green) and K63 chains 
(undetectable). No signal was detected for the replicate Δubc1_1 most likely due to technical issues with the 
electrospray. 
Extended growth of yeast expressing Htt(ExonI)25Q-GFP-Flag in galactose containing 
medium revealed an increase in total fluorescence per cell (~30%) in the ubc1-deletion 
background as compared to wildtype (data not shown). Accordingly, yeast expressing 
Htt(ExonI)25Q-GFP-Flag was grown in galactose containing medium over night and total cell 
lysate was analysed by SDS-PAGE and immunoblotting (Figure 26C). ubc1-deleted and atg1-
deleted cells, which are deficient in lysosomal degradation, showed increased levels of 
Htt(ExonI)25Q-GFP-Flag and additional higher molecular weight bands indicating possible 
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aggregation. A yeast strain deleted for both genes showed cumulative increase in 
Htt(ExonI)25Q-GFP-Flag and the higher molecular weight smear. I aimed to assess the 
ubiquitination status of Htt(ExonI)25Q-GFP-Flag in yeast. To this end, I performed a pilot 
experiment in collaboration with Dr. Oliver Popp from the MS core facility (MDC, Berlin) with 
supervision from Dr. Philipp Mertins. Htt(ExonI)25Q-GFP-Flag was immuno-precipitated 
from lysate of either wild type or ubc1-deleted cells expressing the Htt fusion-protein. Cells not 
harbouring the construct were used as a background control. Samples were prepared in triplicate 
and enrichment of the fusion-protein was assessed by identification of multiple GFP derived 
peptides using shotgun proteomics (Figure 26D). Samples were also subjected to PRM 
measurements, which showed no enrichment of K48 chains (blue), total Ub (green) or Actin 
(red), while K63 chains could not be detected (Figure 26E). In summary, it appears S. cerevisiae 
is not a suitable model system for the study of Ubc1-dependent Htt aggregation. 
2.3 The E2 ubiquitin-conjugating enzyme Ubc3 contains 
C-terminal Ub binding motifs and shows distinctive activity 
towards differently linked Ub probes 
Ubc3 (Cdc34) is an E2 ubiquitin-conjugating enzyme, which generates polyubiquitin linked 
through lysine 48. It encompasses two C-terminal motifs (UBS1 and UBS2), which have been 
reported to bind Ub.83 As part of a collaboration with Dr. Mohit Misra, who studied the 
activation of Ubc3 by the E1 enzyme UBA1 in the group of Prof. Dr. Herrmann Schindelin 
(Julius-Maximillians-Universität, Würzburg), I evaluated the ability of Ubc3 to extend 
preformed Ub chains. Full length Ubc3 (Ubc3-FL), a variant lacking both Ub binding motifs 
(Ubc3ΔC, aa1-178) and a variant additionally lacking a loop region close to the active site 
(Ubc3ΔCΔloop, aa1-178Δ100-113) were purified by Dr. Misra. I tested their activity against a 
panel of Ub probes in single turnover ubiquitination assays (Figure 27A) as introduced in 
section 2.2.3.2. While Ubc3-FL and Ubc3ΔC were both able to efficiently extend different kinds 
of preformed Ub chains, Ubc3ΔCΔloop rapidly formed a covalent bond between E2 and donor 
Ub instead. To test, if this occurs as a result of intramolecular auto-ubiquitination, I performed 
in vitro ubiquitination experiments with untagged and his-tagged Ubc3ΔCΔloop (Figure 27B). 
Both Ubc3ΔCΔloop variants efficiently formed E2-Ub conjugates (lane 1 and 2). His-tagged 
Ubc3ΔCΔloop, which was treated with iodoacetamide (IAA) lost its activity (lane 3). When 
His-tagged and Ubc3ΔCΔloop were both employed in the same reaction, both were 
ubiquitinated (lane 4). If the His-tagged Ubc3 was previously treated with IAA only one band 
corresponding to untagged E2-Ub could be observed, which indicates intramolecular auto-
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ubiquitination (lane 5). Interestingly, turnover of the distal moiety of 63Ub2 in presence of Ubc3-
FL appeared to occur faster than for other probes and also faster than in presence of Ubc3ΔC. 
This suggests Ubc3 might – similar to Ubc1 –preferentially modify K63 chains, but selectively 
target the distal moiety instead of the proximal one. Unlike for Ubc1 this did not coincide with 
an increased turnover of M1Ub2. However, further experiments are required to understand the 
significance of these observations. 
 
Figure 27: In vitro ubiquitination experiments with Ubc3. (A) Different Ubc3-constructs were employed in 
single turnover ubiquitination experiments as introduced in section 2.2.3.2. Samples were taken at indicated time 
points and analysed by SDS-PAGE and fluorescence scan. (B) Tagged and untagged Ubc3ΔCΔloop, which was 
previously treated with IAA or buffer control, was employed in a ubiquitination reaction for 5 min. Samples were 
analysed by SDS-PAGE, fluorescence scan and Coomassie staining.  
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3. Discussion 
3.1 Stimulation of ubiquitin chain assembly by ubiquitin binding 
domains 
3.1.1 Polyubiquitin chain assembly requires coordinated orientation of 
acceptor ubiquitin 
Ubiquitination plays a key role in virtually all cellular processes in the eukaryotic cell. Ubiquitin 
(Ub) is assembled into differently linked polymeric chains, which not only enables versatile 
signalling but also raises unique challenges for the involved molecular machinery. Iterative 
addition of the 8.6 kDa Ub molecule causes significant topological changes after each 
successive step. A process capable of Ub chain assembly needs to coordinate a substrate and 
the respective set of enzymes with a growing Ub chain between them. Moreover, specificity 
needs to be established on multiple levels. First, selective targeting of a substrate and in some 
cases of the correct attachment site within the substrate is required. Second, a defined linkage 
type between Ub molecules must be generated to guarantee the corresponding biological 
outcome. In other words, a specific lysine residue in Ub must be aligned with the active site of 
an enzyme. Third, the appropriate Ub moiety within a Ub chain must be targeted to produce the 
correct chain topology. In most cases, this means that a distal Ub must be aligned with an 
enzyme to enable chain elongation. Conceptually, this could be viewed as particularly 
challenging because a specific unit within identical building blocks must be recruited. 
Consequently, chain elongation should be a self-attenuating process because the chance to 
randomly target the distal Ub moiety decreases with length. However, because chain length can 
determine signal potency, transfer of sufficient Ub moieties must be ensured while the substrate 
is retained at its cognate E3 ligase. Additionally, Ub chain assembly is an energy consuming 
process and is constantly counteracted by the activity of DUBs. Thus, the multiple demands for 
specificity need to be integrated into an efficient process. Which molecular mechanisms do 
chain building enzymes employ to overcome these challenges? 
This question was addressed in this study through detailed characterisation of the two E2 
enzymes Ubc7 and Ubc1. Key experiments which I performed to achieve this goal included 
cell-based assays with S. cerevisiae, protein structure determination and in vitro ubiquitination 
assays. The results show that both E2 enzymes rely on associated ubiquitin binding domains 
(UBDs) to position acceptor Ub (UbA) for an optimal discharge of the donor Ub (UbD). In both 
cases, the respective UBD interacts with a Ub moiety adjacent to the immediate UbA. The 
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necessity for chain building E2 enzymes to act in concert with Ub binding factors emerged as 
an overarching principle over the recent years. Branigan et al.143 revealed through structural 
investigation of the K63 specific enzyme Ubc13 how its co-factor Mms2 (Uev1a in 
S. cerevisiae) aligns UbA with the active site of Ubc13. Moreover, Brown et al.144 showed that 
the activity of the K11 specific E2 enzyme Ube2S is enhanced by binding of UbA by APC11 – 
a subunit of its cognate E3 ligase.  
In the following sections, I discuss the biochemical investigation of Ubc7 and Ubc1, and I 
present reaction mechanisms for Ub chain assembly by both enzymes. In the second part of this 
discussion, I address how the activity of these enzymes may affect the eukaryotic cell. 
3.1.2 Efficient assembly of K48 linked chains by Ubc7 and Cue1 is 
mediated by the Ub binding CUE domain 
 
Figure 28: Model of Ubc7 activation by Cue1. The CUE domain of Cue1 binds individual moieties within a 
Ub chain and Ubc7 is recruited via the U7BR domain. Discharge of donor Ub by Ubc7 is optimally promoted 
when the CUE domain binds to the penultimate Ub moiety. Additional binding sites facilitate Cue1 recruitment 
and further accelerate chain elongation. Figure from von Delbrück et al.1 
Ubc7 was previously reported to be recruited and activated through the U7BR domain of its co-
factor Cue1.84 However, how Ub binding by Cue1 could stimulate chain formation remained 
elusive. In a collaborative effort, we showed through single turnover ubiquitination experiments 
that interaction of the CUE domain of Cue1 with the penultimate moiety of a K48 chain strongly 
promotes Ubc7 activity. NMR binding experiments revealed that the CUE domain of Cue1 
preferentially associates with Ub molecules, to which another Ub was attached through K48. 
This facilitates recruitment of Cue1 to K48 chains over other chain types and increases the 
affinity for K48 chains with increasing length. Intriguingly, we observed higher turnover of 
48x3Ub4 than 48Ub2 in presence of Ubc7/Cue1. In other words, Ub binding by Cue1 prevents 
self-attenuation of Ub chain elongation and self-accelerates this process (Figure 28).  
We found that the interaction between the CUE domain and Ub is well suited for the chain 
elongation process in several ways. Cross-linking the CUE domain to specific positions in K48 
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chains provided clear evidence that binding to the penultimate moiety most effectively 
stimulates elongation reactions with Ubc7. In another line of experiments, the introduction of a 
R42A amino acid substitution into Ub was exploited to disrupt binding of the CUE domain to 
defined sites. The substitution elicited the strongest impact when located at the penultimate 
position of a K48 chain. However, introducing the substitution to more or to other positions 
also reduced Ubc7 activity. It is therefore possible that the CUE domain promotes Ubc7 activity 
not only by positioning the E2 enzyme at a specific location but also by increasing the local 
concentration of the E2 enzyme in proximity to the Ub chain. The CUE domain interacts with 
the conserved hydrophobic patch in Ub, but we found its binding interface to extend to 
additional residues in the C-terminus of Ub attached to K48 of another Ub moiety. This was 
particularly evident for G75 in NMR titration experiments. A prerequisite for this binding mode 
is the exclusion of K48 from the binding interface, which is involved in the recruitment of, for 
example, Cue2.86 This property also minimises the negative effect on reaction rates in 
conditions under which binding of the CUE domain competes with Ubc7 activity 
(section 2.1.2). Based on our PELDOR experiments, we showed that the CUE domain 
associates with and stabilises pre-existing conformations of K48 chains.2 Binding endogenous 
conformations with rather low affinity might aid in iterating binding events with high frequency. 
Possibly this enables the CUE domain to quickly sample different positions within the K48 
chain, which increases the chance for a productive alignment of Ubc7 and reduces the dwell 
time in positions unsuitable for chain elongation.  
We observed de novo diubiquitin assembly by Ubc7, which putatively requires Ubc7 
dimerisation. Chain elongation was more efficient than diubiquitin formation (Figure 10). 
Nevertheless, this finding was particularly intriguing because Ubc7/Cue1 requires a K48 chain 
of two or more moieties for efficient chain elongation. In absence of such a K48 chain as 
scaffold Ubc7 might prime a substrate with diubiquitin to enable subsequent chain elongation. 
The validity of this finding should be tested through identifying a Ubc7 variant impaired only 
in diubiquitin formation, but not in chain elongation, and its effects on substrate degradation 
should be studied in vivo. 
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3.1.3 Assembly of K48/K63 branched ubiquitin chains by Ubc1 is 
dependent on its Ub binding UBA domain 
The UBA domain of Ubc1 was previously reported to facilitate assembly of K48 chains.126 To 
assess its role in enzymatic activity, I compared reaction rates in experiments with either Ubc1 
or only its UBC domain in presence of different acceptor Ub species. Reactions with the full-
length enzyme were compared to only the UBC domain and yielded approximately 25% faster 
turnover of monoubiquitin and 48Ub2. However, this effect was eclipsed by the 6.3 fold increase 
in reaction rate for 63Ub2. This increase is the same order of magnitude as the 12 fold faster 
turnover of 48Ub2 over monoubiquitin by Ubc7/Cue1 under similar reaction conditions.1 
Conversely, turnover of 48Ub2 by full-length Ubc1 was 25% slower than turnover of 
monoubiquitin, which presents a stark contrast to Ubc7/Cue1. Accordingly, NMR binding 
studies showed that the UBA domain binds better to the distal moiety in 48Ub2 than to the 
proximal one. This is the inverse selectivity as observed for the CUE domain. Moreover, the 
UBA domain binds worse to K48 chains, which are the enzymatic product of Ubc1, than to K63 
chains, which have to this point in time not been linked to Ubc1 activity. These findings conflict 
with a designated role of the UBA domain in aiding processivity during assembly of K48 chains.  
Instead, I observed selective activity towards K63 chains. Amino acid substitutions in 63Ub2, 
which either block the acceptor lysine in Ub (K48R) or interfere with binding of the UBA 
domain (R42A), revealed that binding of the UBA domain to the distal moiety enables the UBC 
domain to target K48 in the adjacent proximal moiety. Evidently, the UBA domain of Ubc1 
facilitates the rapid modification of K63 chains to form K48/K63 branched chains – an until 
now little studied chain architecture (Figure 29A). Introducing the K48R substitution into 
different positions of M1Ub2 revealed the same site specificity as observed for 63Ub2. However, 
the initial reaction rate for turnover of 63Ub2 was three times higher than for M1Ub2 despite the 
strong structural similarity between M1 chains and K63 chains. This emphasises the selectivity 
of Ubc1 for K63 chains. Importantly, no factors in S. cerevisiae are thus far known to assemble 
M1 chains. Experiments with chimeric Ubc1, in which the UBA domain was replaced with 
either the CUE domain of Cue1 or the Dsk2 UBA domain, did not allow efficient formation of 
K48/K63 branched chains. These domains share an equivalent fold and the propensity to 
associate with the hydrophobic patch in Ub. Therefore, these results point towards unique 
properties of the Ubc1 UBA domain. Possibly, the binding interface between the UBA domain 
and the UBC domain is disrupted in the chimeric proteins or the dynamics of the process are 
disturbed because of an altered binding affinity for Ub. 
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Unlike the CUE domain, we could not observe a binding preference of the UBA domain for 
individual moieties within the selectively targeted Ub chain. It could be argued that preferential 
association with a specific Ub moiety is less important for the formation of branched chains 
than for chain elongation. The chance to randomly bind the distal Ub in a chain, which is 
required for chain elongation by Ubc7/Cue1, decreases with increasing chain length. However, 
to introduce a branching point into a K63 chain, the UBA domain of Ubc1 could associate with 
any but the proximal moiety. Thus, the chance for a productive binding event increases with 
growing chain length. Ubc1 recruitment to K63 chains under physiological conditions may 
benefit from avidity and thereby compensate for the relatively low binding affinity. Conversely, 
the propensity to bind increasingly long K48 chains is hindered due to the reduced binding 
affinity between the UBA domain and Ub modified at K48. 
 
 
Figure 29: Model of Ubc1 mediated assembly of K48/K63 branched ubiquitin chains. (A) Cartoon model of 
Ubc1 activity. Ubc1~Ub thioester associates with a K63 chain by binding distal Ub (yellow) via the UBA domain 
(red). Ubc1 then attaches the donor Ub (purple) to the adjacent proximal moiety (teal), which leads to the 
generation of a K48/K63 branched chain. (B) Structural model for the transition state of the reaction according to 
Figure 14F. 
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3.1.4 Structural insights into Ubc1 activity 
Based on existing structural information about Ube2K and my experiments on Ubc1, I propose 
a structural model for a transition state during branched chain formation (Figure 29B). This 
transition state relies on three inter-domain interactions. First, the UBA domain binds Ub via a 
canonical UBA:Ub interface through interaction between helix α1 and α3 of the UBA domain 
with the hydrophobic patch in Ub. Second, the UBC domain and UBA domain interact through 
a hydrophobic interface, which was reported in crystal structures of Ube2K. Third, the 
immediate acceptor Ub aligns with the UBC domain, which most prominently involves D58-
Y59-N60 in Ub and S81-S82-T84-D123 in Ubc1. This interaction interface was previously 
predicted by HADDOCK modelling.124 The transition state implies that the K63 chain, which 
is part of the interaction, assumes an open conformation. This indicates that Ubc1 like 
Ubc7/Cue1 might rely on conformational selection for binding. It would be interesting to 
experimentally asses how Ubc1 affects the conformational space of 63Ub2. 
I investigated the interaction between Ubc1 and K63 chains through X-ray crystallography. To 
this end, I purified and crystallised a complex of Ubc1, which was enzymatically conjugated to 
a pseudo donor Ub and chemically cross-linked to 63Ub2. However, the distal moiety of 63Ub2 
could not be observed due to a lack of electron-density in the X-ray crystallographic structure. 
The poor electron density for the distal moiety in 63Ub2 could be explained by the inherently 
high flexibility of K63 chains.72 Moreover, it appears this Ub unit is not coordinated with any 
of the other complex components – unlike the proximal unit in 63Ub2, which tightly binds to the 
UBC domain, and unlike UbD, which in turn associates with a symmetry related UBA domain. 
Inter-complex binding or oligomerisation of Ubc1~Ub provide no obvious implication for Ubc1 
activity. Although my structural investigation failed to capture a meaningful overall complex 
architecture, the value of the structure lies in the experimental determination of the binding 
interfaces between the UBC domain of Ubc1 and acceptor Ub (UBC:UbA) as well as the binding 
interface between the UBA domain and Ub (UBA:Ub). The UBC:UbA interface revealed that 
K63 in UbA points towards the helix α4 in Ubc1, where the UBA domain is located. 
While Merkley and Shaw105 report high flexibility in the linker region connecting the UBC 
domain and the UBA domain in an NMR solution structure of Ubc1, multiple crystal structures 
of Ube2K show close association between the UBC domain and the UBA domain (PDB IDs: 
5DFL, 6IF1, 3E46, 3F92, 3K9O, 3K9P). The significance of this association for enzymatic 
activity could not directly be inferred from my experimental data. An important observation in 
this context was the reduced activity of Ubc1 towards M1 chains as compared to K63 chains, 
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despite their structural similarity. The introduction of Ub(K48R) into M1Ub2 disturbed Ubc1 
activity with the same position dependent effect as for 63Ub2. However, the reaction rate was 
three times lower than in reactions with 63Ub2. This indicates that the flexibility between UBC 
domain and UBA domain cannot compensate for the minor structural differences between 
M1Ub2 and 63Ub2. Alternatively, one could speculate about a model, in which the interaction 
between the UBC domain and the UBA domain is not required to provide an adequate binding 
interface for 63Ub2. Instead, the binding of 63Ub2 could bring the UBA domain and the UBC 
domain in contact, which in turn might facilitate a discharge of UbD. In preliminary aminolysis 
experiments with the UBC domain I could not observe a stimulating effect upon addition of the 
UBA domain separately (data not shown). However, the exact role of association between the 
UBC domain and the UBA domain during branched chain formation still needs to be clarified. 
3.1.5 Coordination of acceptor ubiquitin is mediated through low affinity 
interactions 
In order to quantify the binding parameters by conventional biophysical methods (e.g. ITC, 
SPR, MST), a ligand typically needs to be employed at concentrations several times higher than 
the respective Kd value. For very low affinity protein-protein interactions, this might not be 
feasible. In the MST experiments presented in this study, dissociation constants could not 
successfully be determined. Although high ligand concentrations were employed, which caused 
visible viscosity in the Ubc1 stock solution, binding of Ub could not be saturated. Proper 
quantification might also have failed as thermophoretic mobility of Ub could only be measured 
at a relatively low pH of 6.2. This might interfere with physiological binding properties of Ubc1. 
We determined binding affinities to individual Ub moieties in 15N-labelled diubiquitin probes 
by NMR titration experiments. The Kd values for binding the Ub moiety, which enables Ub 
transfer, reflected a relatively low affinity with 192 µM and 84 µM for the UBA domain and 
the CUE domain respectively. Similarly, the Kd value for binding of monoubiquitin by Mms2, 
which activates the E2 Ubc13, was reported to be 30 µM.145 Compared to the binding of Ub 
moieties, which do not enable chain formation, we observed no more than a 2-fold difference 
in dissociation constants. Despite the low binding affinity and weak preference towards the 
correct moieties, these interactions play a pivotal role for the activity of the respective E2 
enzymes. Ultimately, single turnover ubiquitination experiments provided a clearer picture of 
chain type preference than binding assays. Binding of Ub might not only be necessary to recruit 
these E2 enzymes to a specific position, but also to increase the dwell time of the UBC domain 
in proximity to the correct UbA. This might be required to enhance the chance of a productive 
interaction between enzyme and substrate. The set of acceptor Ub species generated in this 
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study was used for a first line of experiments on the K48 specific E2 enzyme Ubc3. Similar to 
Ubc1, Ubc3 – dependent on its C-terminal extension – showed enhanced activity in the presence 
of 63Ub2, but in contrast to Ubc1 not in the presence of M1Ub2. Moreover, Ubc3 preferentially 
targeted the distal moiety in 63Ub2, which is the inverse selectivity observed for Ubc1.  
In conclusion, Ub binding interfaces guiding Ub chain assembly may be inherently difficult to 
discover and characterise. While this study focusses on UBDs, other Ub binding interfaces can 
be comprised of a single helix146 or be a small part of an otherwise large protein complex147. 
Low affinity Ub binders might rely on conformational selection as a general pattern. Thus, 
approaches exploiting simulated docking between the enzymes’ surface and known preferential 
conformations of their cognate Ub chains could provide valuable insights. Moreover, methods 
which rely on the immobilisation of a bait protein in high density on a surface, could be used 
to characterise these extremely weak protein-protein interactions. 148 Thereby, the necessity for 
very high ligand concentrations in traditional methods could be circumvented. 
3.2 Biological implications 
3.2.1 Modulation of E2 enzyme activity in vivo 
We found that amino acid substitutions in Cue1, which reduced the binding affinity towards 
Ub, also impaired its ability to stimulate chain assembly by Ubc7. Moreover, introducing these 
Cue1 variants into S. cerevisiae impaired degradation of the ERAD-substrate Ubc6. This 
indicates that Ubc7 and Cue1 are fine-tuned machinery, as other factors that modulate the length 
of existing K48 chains did not override the changes in enzyme kinetics. This includes the UFD 
pathway which extends K48 chains47,149 and DUBs. Moreover, ubiquitin receptors in the 
downstream acting factors – such as Cdc48, which is required for substrate dislocation150, or 
the proteasome – could be indifferent towards slightly altered chain length distribution in the 
substrate. Taken together this highlights that the dynamics in polyubiquitin chain assembly have 
an impact on a cellular level and, by extension, may affect the entire organism. 
While Ubc7 has a well-established role in ERAD, Ubc1 has been implicated in various 
biological processes and shown to cooperate with multiple different E3 ligases. The role of the 
UBA domain uniquely contained in Ubc1 and its homologues remains unclear. Ubc1 has been 
implicated in cell cycle progression110, in ERAD21, in nuclear protein quality control151 and in 
heat stress tolerance109,152. I aimed to replicate reported functions of Ubc1 in several exploratory 
experiments to assess the impact of the UBA domain. In collaboration with Dr. Janine Kirstein 
(FMP, Berlin), we identified that depletion of the Ubc1 orthologue ubc-20 in C. elegans induced 
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the aggregation of huntingtin (Htt) with a short polyQ stretch. The human homologue Ube2K 
or HIP2 (“huntingtin interacting protein 2”) has previously been shown to be involved in the 
formation of Htt aggregates.117 Interestingly, imbalance of K48 and K63 chains has also been 
linked to formation of these toxic Htt aggregates153. Thus, I reconstituted expression of Htt-GFP 
in S. cerevisiae. I observed the previously reported aggregation propensity in dependence of the 
length of its polyQ repeats. However, I could not detect an influence of Ubc1 in this context. 
Despite being a useful system to study the aggregation of Htt, yeast might lack important 
components which are present in cells endogenously harbouring Htt. Moreover, Htt 
overexpression might overburden the ubiquitination machinery, resulting in less ubiquitination 
or a different pattern than under physiological expression levels. To validate a direct effect of 
Ubc1 and its homologues on polyQ proteins, further experiments should be conducted. A first 
step could be to quantitatively assess Ub chain types on Htt from C. elegans depleted of ubc-20. 
The investigation of Ubc1 in S. cerevisiae was complicated by poor expression of constructs 
lacking the UBA domain or harbouring mutations in the sequence coding for the QGF motif 
(aa179-181), which has previously been reported to be pivotal in Ub binding130. The 
destabilisation of Ubc1 missing the UBA domain has also been observed by others.123,154 I 
hypothesised that a correctly folded UBA domain might be necessary to stabilise Ubc1 in the 
cellular environment through interactions with the UBC domain. Therefore, I tested amino acid 
substitutions in solvent exposed side chains and I identified the Ubc1-EEAA variant (E211A, 
E212A) to be expressed at similar levels as wild type Ubc1 (data not shown). Nonetheless, this 
variant was impaired in Ub binding and branched chain assembly (Figure 16, Figure 20). It 
could be exploited to identify UBA-domain-dependent processes in established Ubc1 
phenotypes. Alternatively, a yeast strain harbouring such a variant could be employed in an 
unbiased screening approach to identify novel substrates of Ubc1. 
3.2.2 Signalling capacity of K48/K63 branched chains 
In the pursuit to identify the function of the UBA domain, Ubc1 unexpectedly proved to 
preferentially assemble K48/K63 branched chains. These unusual Ub signals have only recently 
been identified in mammalian cells.58 Ohtake et al. show a possible role of such chains in 
NF-kB-signalling and retargeting of substrates decorated with K63 chains to proteasomal 
degradation. We were able to show that the assembly of K48/K63 branched chains is conserved 
in S. cerevisiae and thus probably in all eukaryotic organisms. However, their detailed function 
remains to be explored. As the NF-kB-signalling pathway is not conserved in yeast, Ubc1 and 
its homologues most likely affect other cellular processes. It will be interesting to see if they 
3. Discussion 
68 
partake in editing of Ub chains to retarget substrates modified with K63 chains for proteasomal 
degradation or function in other ways. The first step in addressing this question will be to 
validate the effect of Ubc1 on abundance of K48/K63 branched chains in yeast. 
There are indications that Ub binders selective for certain linkages can still bind their cognate 
chain type, even if it is integrated into branched chains.60 Alternatively, K48 modification of a 
K63 chains might disrupt binding of downstream factors due to the proximity of K48 to the 
hydrophobic patch in Ub. K48/K63 branched chains could also provide a unique interface for 
selective binders. Future studies could identify such binders by performing pull-down 
experiments coupled with mass spectrometry155 using differently linked Ub chains and 
branched chains as bait. Reversibly, binders specific for branched chains or antibodies 
engineered for their detection could help to reveal substrates, which are decorated with these 
signals. 
3.3 Concluding remarks 
Ubiquitination was discovered as a mechanism for protein degradation in the 1980s. Since then, 
it emerged as a highly versatile modification governing widespread functions in the eukaryotic 
cell. Researchers uncovered the different ways in which Ub chains can be assembled, and how 
post-translational modifications of Ub like phosphorylation and acetylation change its 
signalling capacity. This led to a much more sophisticated view on protein ubiquitination in cell 
biological studies. However, there is still much to learn. The different chain types and PTMs of 
Ub have been metaphorically described as the “words” of the Ubiquitin Code.156 In extension, 
we need yet to understand basics about its “grammar”. This entails answering questions such 
as: What is the interdependence between chains with different linkage types as well as Ub 
decorated with small chemical groups? Is there a hierarchy in co-occurring modifications? How 
does chain length and the presence of multiple modifications affect Ub signalling? What role 
does chain topology play as observed, for example, in mixed and branched chains? Moreover, 
there is still a significant gap to close between the mechanistic investigation of ubiquitination 
and its physiological outcomes. Understanding the most complex regulatory network in the 
eukaryotic cell carries great promise for insights into human development and disease. By 
providing a functional link between K63 chains and K48 chains as well as Ub chain assembly 
and the activity of UBDs, this study contributes to the endeavour of achieving an integrated 
understanding of the Ubiquitin Code.  
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4. Experimental Procedures 
4.1 Materials 
4.1.1 Bacterial strains 
XL1-blue cells (Aligent Technologies) 
BL21 Rosetta 2 cells (Novagen) 
DH5a competent E. coli (NEB) 
 
4.1.2 Yeast strains 
Most yeast strains were derived from DF5157 (S288C), which has the following genetic 
background: MAT a/alpha trp1-1(am) his3-Δ200 ura3-52 lys2-801 leu2-3,-112. 
name genotype mat 
yWO1 DF5 alpha 
yWO2 DF5 a 
yWO5 DF5 ∆ubc1::HIS3 alpha 
yWO6 DF5 ∆ubc1::HIS3 a 
yTX106 DF5 ∆ubc7::LEU2 alpha 
yTX105 DF5 ∆cue1::HIS3 alpha 
 
Sub328 DF5 ubil-Δ1::TRP1 ubi2-Δ2::URA3 ubi3Δub-2 ubi4-Δ2::LEU2 +[pUB146] 
+[pUB100] (Spence et al.23) 
a 
yLP12 sub328 + pLP048 –[pUB146] a 
yLP13 sub328 + pLP105 –[pUB146] a 
yLP26 sub328 + pLP048 –[pUB146] Δubc1::URA3 a 
 
yTX1251 W303 background: trp1∆1, his3-11,15, ura3-52, lys2-801, leu2-3,-112 a 
yLP14 yTX1251 GAL-Htt25Q_p303::HIS3 a 
yLP15 yTX1251 GAL-Htt103Q_p303::HIS3 a 
yLP16 yTX1251 Δubc1::URA3 a 
yLP17 yTX1251 GAL-Htt25Q_p303::HIS3 Δubc1::URA3 a 
yLP18 yTX1251 GAL-Htt103Q_p303::HIS3 Δubc1::URA3 a 
yLP21 yTX1251 GAL-Htt25Q_p303::HIS3 ∆atg1::kanMX a 
yLP22 yTX1251 GAL-Htt25Q_p303::HIS3 ∆atg1::kanMX Δubc1::URA3 a 
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4.1.3 Plasmid list 
 
name insert backbone origin 
 
GST-tagged Ubc1 
pTX449 GST-Ubc1 (GST cleavable with HRV3C) pGex-6p1 this study 
pTX457 GST-UBC (Ubc1,1-150) pGex-6p1 this study 
pTX432 GST-UBA (Ubc1,151-215) pGex-6p1 this study 
pTX454 GST-Ubc1 LRV (QGF179-181) pGex-6p1 this study 
pTX451 GST-Ubc1 K93R pGex-6p1 this study 
pTX459 GST-UBC K93R pGex-6p1 this study 
pLP034 GST-Ubc1 EEAA (E211,E212) pGex-6P1 this study 
pLP106 GST-Ubc1 K93R, EEAA (E211,E212) pGex-6P1 this study 
pLP099 GST-Ubc1 K93R, T84D pGex-6p1 this study 
pLP101 GST-Ubc1 K93R, E211R pGex-6p1 this study 
pLP102 GST-Ubc1 K93R, R192Q pGex-6p1 this study 
 
UBC domain of Ubc1(2-149) with UBA domain of Dsk2 or CUE domain of Cue1 
pLP001 GST-Ubc1-3xGS-UBA(Dsk2) pGex-6p1 this study 
pLP002 GST-Ubc1-6xGS-UBA(Dsk2) pGex-6p1 this study 
pLP003 GST-Ubc1-12xGS-UBA(Dsk2) pGex-6p1 this study 
pLP004 GST-Ubc1-3xGS-CUE-GS-6xHis pGex-6p1 this study 
pLP005 GST-Ubc1-6xGS-CUE-GS-6xHis pGex-6p1 this study 
pLP006 GST-Ubc1-12xGS-CUE-GS-6xHis pGex-6p1 this study 
pLP007 GST-Ubc1(K93R)-3xGS-CUE-GS-6xHis pGex-6p1 this study 
pLP008 GST-Ubc1(K93R)-6xGS-CUE-GS-6xHis pGex-6p1 this study 
pLP009 GST-Ubc1(K93R)-12xGS-CUE-GS-6xHis pGex-6p1 this study 
pLP010 GST-Ubc1(K93R)-3xGS-UBA(Dsk2) pGex-6p1 this study 
pLP011 GST-Ubc1(K93R)-6xGS-UBA(Dsk2) pGex-6p1 this study 
pLP012 GST-Ubc1(K93R)-12xGS-UBA(Dsk2) pGex-6p1 this study 
 
Other enzymes 
pTX475 GST-Ubc4(Δintron) pGEX-6p1 this study 
pLP016 GST-Ubc4(Δintron)-K91R pGEX-6p1 this study 
pMD28 GST-Ubc13 pGEX4T1 Mansour et al.158 
pMD29 GST-Uev1a pGEX6p1 Mansour et al.158 
pMD27 Ube2K pET28 gift from Prof. R. Klevit, 159 
pLP054 Ube2K K97R 6His pET28 this study 
pLP061 GST-Ubc20 pGex-6p1 this study 
pTX315 Hrd1-RING (325-550) pGex-6p1 Bagola et al.84 
pTX481 hUbe1-6xHis pET21d Berndsen and Wolberger160 
pTX249 Ubc7 pGEX6p1 Bagola et al.84 
Ubc7-U7BR Ubc7(FL)-GG-Cue1(147-203, C147S) pET39b(+) Kniss et al.2 
pMD26 Cdc34 pGEX6p1 von Delbrück et al.1 
 
Ub binders 
pSH006 GST-Dsk2-UBA (aa241-374) pGex-6p1 Bagola et al.84 
gp78-CUE 10xHis-Ub19-TEV-gp78CUE (aa453-503) pET39b(+) Kniss et al.2 
OTUB1 His6-GST-3C-OTUB1 C91A (aa1-271) pOPINK Kniss et al.2 
 
Plasmids for structural investigation 
pLP063 6xHis-Smt3-Ubc1 pRSFduett this study 
pLP065 6xHis-Smt3-A-hUb(K48R) pRSFduett this study 
pLP067 UbK48C,G75* pET21d this study 
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name insert backbone origin 
 
Ubiquitin expression experiments 
pMD10 hUb (human ubiquitin, codon optimised for E. Coli) pETM60 von Delbrück et al.1 
pMD16 hUb K48R pETM60 von Delbrück et al.1 
pMD18 hUb K63R pETM60 von Delbrück et al.1 
pLP109 hUb K48R, K63R pETM60 this study 
pMD14 hUb R42A pETM60 von Delbrück et al.1 
pLP107 hUb R42A, K48R pETM60 this study 
pMD11 hUb-6xHis pETM60 von Delbrück et al.1 
pLP090 hUb-6xHis Q62R pETM60 this study 
pMD17 hUb-6xHis K48R pETM60 von Delbrück et al.1 
pMD15 hUb-6xHis R42A pETM60 von Delbrück et al.1 
pLP108 hUb-6xHis R54A pETM60 this study 
pLP079 linUb2-6xHis pRSF Duet this study 
pLP110 linUb2-6xHis K48R(proximal) pRSF Duet this study 
pLP111 linUb2-6xHis K48R(distal) pRSF Duet this study 
 
Ubiquitin for fluorescent labeling (MST assays, in vitro ubiquitination) 
pMD12 human ubiquitin S20C (E. coli codon optimised pETM60 von Delbrück et al.1 
pMD13 hUb S20C - 6xHis PETM60 von Delbrück et al.1 
pLP77 hUb-SGCG-6xHis pRSF duet this study 
 
Cue1 costructs for protein expression (NMR titration and activity assays) 
Cue1-CUE Ub19 – TEV – Cue1 (25-203, C147S) Ub19 – His6 pET39b(+) von Delbrück et al.1 
pTX410  Cue1 (ΔTM,24-203) pGex-6p1 pGex-6p1 Bagola et al.84 
pMD23  Cue1 E96A pGex-6p1 von Delbrück et al.1 
pMD24  Cue1 E100A pGex-6p1 von Delbrück et al.1 
pMD25  Cue1 L103A pGex-6p1 von Delbrück et al.1 
pTX411  Cue1 RGA (L76,A77,P78) pGex-6p1 von Delbrück et al.1 
 
Degradation of Ubc6 in presence of binding deficient Cue1 mutants 
pTX397 Cue1 (bp -450 bis +609) pRS415 Bagola et al.84 
pLP022 Cue1 E96A pRS415 von Delbrück et al.1 
pLP023 Cue1 E100A pRS415 von Delbrück et al.1 
pLP024 Cue1 L103A pRS415 von Delbrück et al.1 
pTX386 Cue1 RGA pRS415 Bagola et al.84 
 
Expression of mutant ubiquitin in yeast 
pUB100 expression of Ubi1 tail - Spence et al. 23 
pUB146 Ub expression plasmid under GAL promoter (URA3) - Spence et al. 23 
pGR295 10xHis-Ub - Provided by Gwenael Rabut 
pLP048 10xHis-Ub R54A pGR295 this study 
pLP105 10xHis-Ub R54A, K63R pGR295 this study 
pLP069 Ubc1(URA) deletion-cassette pBluescript this study 
 
Introduction of Htt into S. cerevisiae 
Addgene 
15576 
GAL Htt(Exon1)-25Q+ProGFP-FLAG p303 Duennwald et al.142 
Addgene 
15577 
GAL Htt(Exon1)-103Q+ProGFP-FLAG p303 Duennwald et al.142 
  
4. Experimental Procedures 
72 
4.1.4 Media and Buffers 
4.1.4.1 Media for Yeast cultures 
Minimal medium (SD) – 0.67% yeast nitrogen base without amino acids, 2% glucose, 20 mg/l 
L-histidine, 30 mg/l L-leucine, 30 mg/l L-lysine, 20 mg/l L-tryptophan, 20 mg/l 
adenine sulfate, 20% uracil 
Full medium (YPD) – 2% BactoTM peptone, 1% BactoTM yeast extract, 2% glucose, pH5.5 
adjusted with HCl 
For preparation of growth plates 2% Agar-Agar was included in the respective medium. 
4.1.4.2 Media for bacterial growth 
Lysogeny broth (LB) – 1% BactoTM tryptone, 0.5% BactoTM yeast extract, 1% NaCl 
Terrific broth (TB) – 1.2% BactoTM tryptone, 2.4% BactoTM yeast extract, 0.4% glycerol, 
17 mM KH2PO4, 72 mM K2HPO4 
Super Optimal broth with Catabolite repression (SOC) – 2% BactoTM tryptone, 0.5% BactoTM 
yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 0.2% glucose 
For preparation of growth plates 2% Agar-Agar was included in LB medium. 
Selective antibiotics were used at a final concentrations of 50 µg/ml for Ampicillin or 25 µg/ml 
for Kanamycin. Plates for blue-white screening contained 1 mM IPTG and 400 µM X-Gal 
(5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside). 
4.1.4.3 Commonly used buffers 
10x PBS – 1.37 M NaCl, 27 mM KCl, 101 mM Na2HPO4, 18 mM KH2PO4 (pH 7.5) 
10x TBT – 0.5 M Tris/HCl pH 7.5, 1.5 M NaCl, 1% Tween20 
4x SDS sample buffer – 250 mM Tris/HCl pH 6.8, 40% glycerol, 8% SDS, 0.05% 
bromophenol blue (including 100 mM DTT unless indicated as 'non-reducing') 
4x Urea sample buffer – 8 M Urea, 200 mM Tris/HCl pH 6.8, 5% SDS, 0.1 mM EDTA, 
0,03% Bromophenol blue (including 50 mM DTT unless indicated as 'non-reducing') 
4.1.5 Protein and DNA standards 
ColorPlus Prestained Protein Marker, Broad Range (New England Biolabs) 
Protein Molecular Weight Marker (Fermentas) 
1 kb DNA Ladder (Invitrogen) 
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4.1.6 Antibodies 
Antibody dilution source 
   
polyclonal α-Cdc48 antibody 1:10.000 Neuber et al.161 
polyclonal α-Cue1 antibody 1:1000 Bagola et al.84 
monoclonal α-GFP antibody 1:1000 Living colors (JL-8) 
monoclonal α-Ub antibody 1:5000 Santa Cruz Biotechnology (P4D1) 
polyclonal α-Ubc1 antibody 1:10.000 this study 
polyclonal α-Ubc6 antibody 1:10.000 Walter et al.162 
polyclonal α-Ubc7 antibody 1:10.000 Bagola et al.84 
polyclonal α-Sec61 antibody 1:10.000 Biederer et al. 102 
   
HRP-conjugated polyclonal α-mouse-IgG (rabbit) 1:10.000 Sigma (A9044) 
HRP-conjugated polyclonal α-rabbit-IgG (goat) 1:10.000 Sigma (A0545) 
 
4.1.7 Consumables 
Amicon Ultra centrifugal filters (MWCO: 3K/10K/30K) Millipore 
BioMax MR Film, Kodak 
cOmplete EDTA-free Protease Inhibitor Cocktail (Roche) 
electroporation cuvettes (Carl Roth PP39.1, column width 2 mm) 
Expand High Fidelity PCR System (Roche) 
Falcon® 15mL High Clarity PP Centrifuge Tube (neolab) 
Falcon® 50mL High Clarity PP Centrifuge Tube (neolab) 
Glass Beads 0.5 mm dia. (BioSpec Products) 
JetStar 2.0 Plasmid Purification Midi Kit (Genomed) 
JetStar 2.0 Plasmid Purification Mini Kit (Genomed) 
NAP-5 prepacked Sephadex G-25 columns (GE Healthcare) 
Zeba Spin Desalting Columns (ThermoFisher) 
Pfu Ultra HF DNA-Polymerase (Agilent Technologies) 
pGEM-T Easy Vector System (Promega) 
pH-Fix colour-fixed indicator sticks (Machery-Nagel) 
Phusion High-Fidelity DNA Polymerase (NEB) 
QIAEX II Gel extraction kit (500) (QIAGEN) 
QuikChange Site Directed Mutagenesis Kit (Agilent Technologies) 
Sarstedt Inc Cuvette Semimicro 1.6ml 
SnakeSkin Dialysis Tubing (ThermoFischer) 
Whatman chromatography papers (Carl Roth) 
Wizard SV Gel and PCR Clean-Up System (Promega)  
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4.1.8 Devices 
ÄKTA pure protein purification system (GE Healthcare) 
Superdex 75 Increase 10/300 GL 
Superdex 200 Increase 10/300 GL  
HiLoad Superdex 16/600 75p 
HiLoad Superdex 26/600 75p 
HiTrap SP HP cation exchange chromatography column 
HiTrap Q HP anion exchange chromatography column 
Capacitance Extender 1652087 (Bio-Rad) 
centrifuge 5415D (Eppendorf) 
centrifuge 5417R (Eppendorf) 
centrifuge 5424 (Eppendorf) 
DC1 W13 Heating Water Bath (Haake) 
Electrophoresis Migthy Small II (Hoefer) 
EmulsiFlex-C5 (Avestin) 
Gene Pulser 1652076 (Bio-Rad) 
HE 33 Mini Submarine Electrophoresis Unit (Hoefer) 
Innova 44 Incubator Shaker (New Brunswick) 
IPP 500 Refrigerated Incubator (Memmert) 
LI-COR Odyssey imaging system (LI-CORE Biosciences) 
LKB MultiTemp II Water Bath (Pharmacia) 
Migthy Small Transfer Tank TE22 (Hoefer) 
Mini Horizontal Agarose Electrophoresis Unit HE33 (Hoefer) 
NanoDrop 2000 spectrophotometer 
Optima Max-XP Ultracentrifuge (Beckman Coulter) 
pH meter (Schott) 
Primus 25 advanced Thermocycler (peQlab) 
Pulse Controller 1652098 (Bio-Rad) 
RCT basic IKAMAG safety control universal hot plate magnetic stirrer (IKA) 
Refrigerated centrifuge Sigma 4K15 
Sorvall RC 6 Plus Centrifuge (Thermo Scientific) 
Thermomixer Compact (Eppendorf) 
Typhoon FLA 9500 laser scanner (GE Healthcare) 
Ultrospec 3100 pro UV/Vis spectrophotometer (GE Healthcare/Amersham) 
Vibrax VXR basic (IKA Shakers) 
Vortex-Genie 2 (Scientific Industries) 
4.1.9 Software 
ACD/ChemSketch 
Adobe Illustrator 
Adobe Photoshop 
ApE (A plasmid Editor) 
Coot 0.8.9 (Crystallographic Object-Oriented Toolkit) 
Igor Pro 6 (WaveMetrics) 
Image Studio (LI-COR Biosciences) 
ImageJ 1.51n 
JabRef 4.1 
Microsoft Office (Excel, OneNote, PowerPoint, Word) 
Phoenix suite 1.13-2998 
SnapGene Viewer 
UCSF Chimera 
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4.2 Methods 
4.2.1 Molecular Biology 
4.2.1.1 Molecular Cloning 
4.2.1.1.1 Preparation of plasmid DNA 
Electrocompetent XL-1 cells were transformed with the desired vector and grown on agar plates 
containing selective antibiotics at 37°C. Single colonies were picked, inoculated in LB medium 
with selective antibiotics and grown at 37°C overnight in a shaking incubator. Plasmid DNA 
was purified either from 2 ml liquid culture using JetStar 2.0 Plasmid Purification Mini Kit 
(Genomed) or from 50 ml liquid culture using the JetStar 2.0 Plasmid Purification Midi Kit 
(Genomed) according to manufacturer’s instructions. The precipitated DNA was resuspended 
in 50 µl ddH2O. DNA concentration and purity was assessed by measuring absorption at 
260 nm and 280 nm using a NanoDrop 2000 spectrophotometer. The plasmids created in the 
framework of this thesis were validated by analytical restriction digest and by DNA sequencing 
(LGC genomics). 
4.2.1.1.2 Polymerase chain reaction (PCR) 
DNA fragments were amplified from a C. elegans cDNA preparation provided by Dr. Janine 
Kirstein (ubc-20), from yeast genomic DNA or from plasmids. PCR reactions with 50-200 ng 
template DNA were performed in a 50 µl reaction volume in aqueous solution containing 1 µl 
of a 10 mM dNTP stock, 1 µl of a forward and reverse primer solution each (10 µM) as well as 
buffer and polymerase. When using the Pfu Ultra DNA polymerase from stratagene 5 µl of the 
10x buffer supplied by the manufacturer and 1 µl polymerase solution were added. When using 
the Phusion High-Fidelity DNA polymerase from NEB 10 µl of the 5x buffer supplied by the 
manufacturer and 1 µl polymerase solution were added. Typically the reaction mix was run 
through the following PCR program: 5 min at 95°C (DNA denaturation), 25-30 cycles of 45 s 
at 95°C (denaturation), 45 s at 48-58°C (annealing), 30 sec per 1 kbp at 68°C with the Pfu 
polymerase or 72°C with the Phusion polymerase respectively (elongation). At the end of the 
program, a final elongation step was performed for double the time as during cycling before the 
reaction was cooled to 8°C and stored. 
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4.2.1.1.3 DNA restriction digest 
Plasmids were digested in a total reaction volume of 50 µl with restriction enzymes from NEB 
and 5 µl 10x CutSmart buffer supplied with the enzymes. For integration of Ubc1-inserts into 
pGex-6p1 1 µl of SalI-HF and 1 µl BamHI-HF (20,000 units/ml, NEB) were used. The reaction 
mix was incubated for 2 h at 37°C and the products separated by agarose gel electrophoresis. 
4.2.1.1.4 DNA ligation 
DNA inserts and linearised vector backbones from restriction digests were purified from 
agarose gels. They were mixed approximately in a 3 to 1 molar ratio in a total reaction volume 
of 20 µl and a total DNA amount of 0.5-4 µg. The ligation mix contained 1 µl T4 DNA ligase 
and 2 µl 10x ligation buffer from the pGEM-T Easy Vector Systems kit (Promega). The mix 
was incubated over night at 4°C or for 1h at RT before transformation into electrocompetent 
XL-1 cells. 
4.2.1.1.5 Agarose gel electrophoresis for DNA analysis 
Agarose gel electrophoresis was performed in order to separate DNA fragments by their 
molecular weight. Agarose gels were prepared with either 2% agarose for detection of 
fragments smaller than 1 kbp or otherwise with 1% agarose in 1x TAE buffer (40 mM Tris/HCl 
pH 8.2, 0.14% acetic acid, 1 mM EDTA). Agarose was melted by microwaving and after 
cooling down to approximately 50°C mixed with RedSafe (1:30.000), which is required for 
DNA detection under UV light. Samples were mixed with DNA sample buffer, added to agarose 
gels in 1x TAE buffer and run for 10-20 min at 100 V. For fragments larger than 500 bp sample 
buffer was 50% glycerol, 5 mM EDTA and 0.1% (W/V) Bromophenol blue. For fragments of 
500 bp and smaller 0.25% Orange G was used instead of Bromophenol blue. Gels were then 
analysed using a UV-Transilluminator Gel-Doc (peQLab). 
4.2.1.1.6 Purification of DNA from agarose gels 
To purify DNA from agarose gels, the desired fragments were viewed on a UV-Transilluminator 
and excised using a scalpel. To separate DNA from agarose the kit Wizard SV Gel and PCR 
Clean-Up System (Promega) was used according to manufacturer’s instructions. In short, the 
agarose gel pieces were melted in a solution of guanidine isothiocyanate at 50°C and DNA was 
immobilised on the surface of silica. After multiple wash steps, DNA was eluted from the silica 
by addition of 10-20 µl ddH2O and then used for DNA ligation. 
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4.2.1.1.7 Gibson assembly 
Cloning of inserts into pRSFduett and pET21d was achieved by Gibson assembly as described 
elsewhere.163 Gibson assembly relies on primers, which amplify the insert and backbone with 
30-50 bp complementary overhangs in two separate PCR reactions. Equimolar amounts of 
reaction products were combined and incubated with a Gibson assembly mix. The mix 
contained Phusion DNA polymerase ,T5 exonuclease and DNA ligase. The T5 exonuclease 
removes basepairs from the annealed strands, producing gaps, which are then filled by the 
polymerase. The DNA ligase seals the nicks between inserts and backbone. Gibson assembly 
mix was prepared by the biochemical core facility of the MPIB (Martinsried). 
4.2.1.1.8 Quickchange PCR 
In order to introduce point mutations or delete one to three codons from a plasmid Quickchange 
Site Directed Mutagenesis kit by Agilent Technologies was used according to manufacturer’s 
instructions. A reaction mix with 5 µl of 10x reaction buffer, 10 ng DNA template, 1 µl of a 
10 µM forward primer solution, 1 µl of a 10 µM reverse primer solution, 1 µl dNTP mix, 3 µl 
DMSO and 1 µl PfuUltra HF DNA polymerase was added to a total reaction volume of 50 µl 
in ddH2O and run with the following PCR program: 1 min at 95°C (DNA denaturation), 25-30 
cycles of 50 s at 95°C (denaturation), 50 s at 55-65°C (annealing), 1 min per 1 kbp at 68°C. 
After cycling a final elongation step was performed for double the time before the reaction was 
cooled to 8°C and stored. 3 µl of the reaction mix were transformed into XL-1 cells and plated 
onto agar plates with selective antibiotics. Single colonies were picked and inoculated in LB 
medium with antibiotics for DNA preparation. 
4.2.1.1.9 Chromosomal gene modification in S. Cerevisiae 
In order to delete genes in S. cerevisiae and to attach carboxy-terminal epitope tags to proteins 
of interest methods were applied, which rely on integration of DNA cassettes into the genome 
through homologous recombination.164,165 DNA cassettes were generated by PCR-reactions and 
harboured a selective marker, which either complemented auxotrophy of a specific strain or 
mediated antibiotic resistance. This enabled selection of transformed cells by growth on 
selective medium. The cassettes were flanked by sequences of typically 20 to up to 50 bp length, 
which were homologous to the targeted gene and guide the DNA to the respective loci, where 
they are integrated through homologous recombination. DNA was transformed into yeast cells 
by heat shock as described in section 4.2.4.2. Transformed cells were transferred onto selective 
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agar plates and incubated at 30°C for two days. Successful transformation was validated by 
analytical PCR reactions and/or SDS-PAGE and immunoblotting. 
4.2.1.1.10 Deletion cassette for ubc1 
All attempts of to delete ubc1 from yeast strains following standard protocols as described in 
the previous section failed. I aimed to optimise recombination deletion of ubc1 in yeast by using 
longer flanking regions. To this end, I performed a restriction digest at endogenous restriction 
sites for BamHI 400bp upstream and for XhoI 270bp downstream of the ubc1 open reading 
frame and ligated the fragment into pBluescript. A restriction site for PstI within the ubc1 open 
reading frame was exploited to introduce the URA selection cassette from pUG72. For ubc1 
deletion 5 µg of the plasmid were digested with BamHI and EcoO109I and run on an agarose 
gel. The released 689bp was purified and transformed into the desired yeast strain. Successful 
deletion was confirmed by growth on selective agar plates, immunoblotting for Ubc1 and 
analytical PCR. 
4.2.1.2 Transformation of electrocompetent E. Coli 
Electro-competent cells were stored in 50 µl aliquots at -80°C and thawed on ice for 
transformation. 1 µl purified plasmid DNA, 2-3 µl PCR product or 5 µl ligation mix were added 
to the cells and then transferred to an electroporation cuvette. Cells were pulsed using Bio-Rad 
Gene Pulser set to 2.5 MV, 25 µF and 200 Ω and incubated for at least 60 min in SOC medium 
at 37°C. Cells were then plated onto LB agar plates with selective antibiotics and grown 
overnight at 37°C. 
4.2.1.3 Transformation of chemically competent E. Coli 
Chemically competent E. coli cells were transformed by heat shock. Cells were incubated with 
the desired DNA (either 1 µl purified plasmid DNA or 3 µl from a 50 µl PCR reaction) for 
30 min on ice. Then, cells were placed in a heat block at 42°C. After 30 s cells were put back 
on ice for a few seconds and mixed with 450 µl SOC medium. Subsequently, cells were 
incubated at 37°C for 1 h and plated onto selective LB agar plates. Single colonies were selected 
after overnight incubation at 37°C. 
4.2.1.4 Expression of recombinant proteins in E. Coli 
For heterologous protein expression BL21 Rosetta cells were transformed with the desired 
expression plasmids and transferred onto selective LB Agar plates. Precultures from single 
colonies were grown over night in LB amp with respective antibiotics in a shaking incubator at 
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37°C. 10 ml of preculture were added to 1l TB medium and grown while shaking in a large 
flask (typically 5l) at 37°C to 1 OD600/ml. The cells were the cooled to 18°C unless otherwise 
indicated and protein expression induced with 500 µM IPTG. Cells were grown over night and 
harvested by centrifugation at 5000 x g for 15 min. Cells were transferred to 50 ml Falcon tubes 
using the desired lysis buffer and either directly used for purification or flash frozen in liquid 
nitrogen. Frozen cell pellets were stored at -80°C. 
4.2.1.5 Expression of isotope-labelled Ub for NMR 
For the expression of 15N labelled Ub monomers with and without 6xHis-tag, cells were grown 
in minimal medium containing 7.5 g/l Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl, 2 mM MgSO4, 
0.1 mM CaCl2, 10 µM FeSO4, 4 g/l glucose, 1 g/l 15NH4Cl, vitamin mix, trace elements mix. 
Vitamin mix final concentrations were 1 mg/l D-biotin, 500 µg/l choline chloride, 500 µg/l folic 
acid, 1 mg/l myoinositol, 500 µg/l nicotinamide, 500 µg/l pantothenic acid, 500 µg/l pyridoxal 
hydrochloride, 50 µg/l riboflavin, 500 µg/l thiamine hydrochloride. Trace element mix final 
concentrations were 50 mg/l EDTA, 8.3 mg/l FeCl3 x 6H2O, 840 µg/l ZnCl2, 0.13 mg/l 
CuCl2x2H2O, 100 µg/l CoCl2 x 6H2O, 100 µg/l H3BO3, 16 µg/l MnCl2 x 6 H2O. 
4.2.2 Biochemistry 
4.2.2.1 Cell lysis of E. Coli 
Cells from 1 l of TB medium were resuspended in 35 ml of the respective lysis buffer. Frozen 
pellets were thawed on ice. Immediately before lysis 1 mM PMSF was added. High pressure 
homogenisation was performed by processing the cell suspension twice in a EmulsiFlex-C5 
(AVESTIN), which was cooled with ice beforehand. Lysate was cleared by centrifugation at 
20.000 x g at 4°C for 20 min. 
4.2.2.2 Purification of GST-tagged proteins 
Lysis buffer for GST-fusion proteins was GST-buffer (50 mM Tris/HCl pH 7.5, 200 mM NaCl 
and 5 mM DTT) with 1 mM PMSF. Cleared lysate was loaded onto a GSTrap FF Column (GE 
Healthcare). Alternatively, resin with immobilised GSH was directly added to the cleared lysate. 
Before binding, resin was equilibrated in GST-buffer. Lysate was incubated with resin for 1 h 
at 4°C. After binding the resin was washed with 5-10 column volumes of GST-buffer. Proteins 
were eluted with GST-buffer containing 20 mM reduced glutathione. Alternatively, proteins 
were released from the resin by digest with PreScission protease (GE) or selfmade GST-tagged 
3C protease protease over night. The next day, the supernatant was collected and the resin 
washed with another column volume of GST-buffer to elute remaining cleaved protein. The 
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protein solution was further purified by size exclusion chromatography (HiLoad 16/600 
Superdex 75pg, GE-Healthcare) in 50 mM HEPES pH 7.5, 200 mM NaCl. Fractions containing 
the desired protein were identified by UV280 absorbance as well as by SDS-PAGE and 
Coomassie staining. Peak fractions were united, concentrated using Amicon Ultra concentrators 
(Millipore), flash frozen in liquid nitrogen and stored at -80°C. 
4.2.2.3 Purification of His-tagged proteins 
Lysis buffer for 6xHis-tagged proteins was either 1xPBS for Ub, 2x PBS with 2 mM 
2-mercapthoethanol for hUbe1 or 50 mM Tris, 200 mM NaCl and 2 mM 2-mercapthoethanol 
for other proteins. Proteins with a 6xHis-tag were purified from cleared lysate by immobilised 
metal affinity chromatography. To this end, cleared lysate was applied to a HiTrap Talon affinity 
column (GE-healthcare). Alternatively, resin with immobilised Co2+-ions (TALON) or Ni+-ions 
(Ni-NTA) was added to the cleared lysate. Resin was equilibrated with lysis buffer prior to 
binding and incubated for 1 h at 4°C with the cleared lysate. Subsequently, resin was washed 
with 5-10 column volumes of lysis buffer. Proteins were eluted with the respective lysis buffer 
including 300 mM imidazole. To cleave off 6xHis-Smt3, fusion proteins were first eluted and 
then incubated with Senp2 protease over night at 4°C while dialysing against buffer without 
imidazole. Typically 1 µg Senp2 protease was used for 50 µg of fusion protein. For dialysis 
SnakeSkin Dialysis Tubing (ThermoFischer) with an adequate molecular weight cut-off was 
used. After incubation, the protein solution was incubated with an equal volume of resin as 
during the initial purification step and incubated for 1 h at 4°C. Untagged proteins were 
collected from the flow-through. After elution, proteins were concentrated using an Amicon 
Ultra concentrator (Millipore) and subjected to size exclusion chromatography. hUbe1 was 
loaded on a HiLoad 16/600 Superdex 200 pg (GE) in 2x PBS, while other proteins were loaded 
on a HiLoad 16/600 Superdex 75 pg in 50 mM Tris/HCl pH7.5, 200 mM NaCl. Fraction 
collection and storage as outlined in previous section. 
4.2.2.4 Purification of untagged ubiquitin monomers 
Purification of untagged Ubiquitin monomers from cleared bacterial cell lysate was performed 
by acidic precipitation of proteins.81 Unlike most other proteins Ubiquitin remains soluble at 
very acidic pH. 70% perchloric acid was added dropwise under stirring to the cleared lysate 
until a total final concentration of 0.7% was reached. The precipitate was cleared by 
centrifugation (20.000 x g for 20 min at 4°C). The supernatant was removed and 10 M NaOH 
solution was titrated to adjust the pH to 7-8, which was confirmed using pH paper. 
Subsequently, monomers were concentrated and further purified by size exclusion 
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chromatography (HiLoad Superdex 26/600 75p) in 50 mM Tris/HCl pH 8.0. Fraction collection 
as in section 4.2.2.2. 
4.2.2.5 Purification of ubiquitin chains 
Ub chains with proximal (i.e. C-terminal) hexahistidine-tag (6xHis) were assembled 
enzymatically in vitro typically in a total volume of 3 to 10 ml. Reactions producing K48 chains 
included 1 μM E1 (hUbe1), 20 μM Cdc34, 900 µM Ub and 600 µM Ub (C-terminal 6xHis) in 
20 mM ATP, 0.9 mM DTT, 9 mM MgCl2 and 50 mM Tris/HCl pH 8. Reactions for K63 chain 
assembly included 1 μM E1 (Ube1), 8 μM Ubc13, 8 μM Uev1a, 1.2 mM Ub and 0.8 mM 
6xHis-Ub in 20 mM ATP, 0.9 mM DTT, 9 mM MgCl2 and 50 mM Tris/HCl pH 8. Ub chain 
formation reactions were incubated at 37 °C for 18 h. 6xHis-tagged chains were removed from 
the reaction mix with metal affinity chromatography with Talon resin. Ub chains obtained from 
the eluate were separated by gel filtration (HiLoad 26/600 Superdex 75pg, GE-Healthcare) in 
PBS, pH 7.5 with a low flow rate (0.3-0.5 ml/min). Fractions containing Ub chains with a 
specific length were collected and concentrated using Amicon Ultra concentrators (Millipore). 
4.2.2.6 SDS-PAGE 
Proteins samples were analysed by sodium dodecylsulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) using Hoefer gel electrophoresis system (Laemmli1970). Samples were mixed 
with either urea sample buffer and incubated at RT or with SDS-PAGE sample buffer and 
incubated at 95°C for 5 min. Seperating gels were cast using 9-18% acrylamide as indicated in 
the experiment, 0,09% bisacrylamide, 500 mM Tris/HCl pH 8.8, 0.1% SDS, 0.02% TEMED 
and 0.1% APS and stored at 4°C until usage. Stacking gels were cast using 9% acrylamide, 
0,06% bisacrylamide,125 mM Tris/HCl pH 6.8, 0.1% SDS, 0.25% TEMED and 2.5% APS. The 
gel chamber was filled with SDS-PAGE running buffer containing 0.3 % Tris base, 1.45 % 
Glycin and 0.1 % SDS. Gels were run at 100V for 10 min and then at 240V until completion. 
Proteins separated by SDS-PAGE were either analysed by fluorescence scanning, western 
blotting or Coomassie staining. Fluorescence scans were performed in a Typhoon FLA9500 
Biomolecular Imager by GE-Healthcare with an excitation wavelength of 473 nm and a LPB 
(510LP) filter for detection. Coomassie staining was performed by shortly boiling the gel in 
Coomassie staining solution (40% MeOH, 10% acetic acid, 0.1% Coomassie Brilliant Blue R-
250) and subsequently incubating it for 5 min in the hot staining solution. Afterwards, the gel 
was transferred to destaining solution (40% MeOH, 10% acetic acid) and also shortly heated in 
a microwave until clear signals were visible. 
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4.2.2.7 Immuno blotting (western blotting) 
Proteins separated by SDS-PAGE were transferred onto a PVDF membrane in a Hoefer Western 
Blotting Chamber at 250 mA for 90 min. Transfer buffer was 1.1% glycine, 0.24% Tris base, 
25% methanol and 0.01% SDS. The transfer membranes were activated in methanol and 
assembled with the SDS-PAGE gel between two layers of Whatman-paper from each side. After 
the transfer membranes were blocked in a 10% skim milk powder (Roth) solution in 1x TBT 
for 15 min. Primary antibody in its respective dilution was added to a 5% skim milk powder 
solution in 1x TBT and incubated with the membrane at 4°C over night. The following day the 
membranes was washed three times with 1x TBT and incubated with secondary antibody in 5% 
skim milk powder solution in 1x TBT for one hour at RT. Another three wash steps with 1x 
TBT were performed followed by three wash steps with 1x PBS. Membranes were analysed by 
adding Western Lightning chemiluminscence solution (Perkin Elmer) and detection either by a 
LiCor Odyssey imaging device or X-ray films (BioMax MR Film, Kodak). 
4.2.2.8 In vitro ubiquitination reactions 
Depending on the experimental design in vitro ubiquitination reactions contained different 
compositions of hUbe1 (0.1-1 µM), E2 enzymes and ubiquitin variants. Unless otherwise 
indicated, all reactions contained 4 mM ATP, 4 mM MgCl2, 0.5 mM DTT and 50 mM Tris/HCl 
pH 7.5. Reactions were started by addition of E2 enzyme. Typically a sample of 15 µl reaction 
mix was taken at indicated time points and the reaction was stopped by addition of urea sample 
buffer. Time courses were then analysed by SDS-PAGE and subsequent fluorescence scan or 
western blotting. 
For chain elongation reactions in section 2.2.3.1 the reactions conditions were 10 µM ubiquitin, 
0.3 µM hUbe1, 2 µM Ubc7/Ubc4/Ubc1 (as indicated), 2 µM cytosolic fragment of Cue1 in 
reactions with Ubc7, 2 µM Hrd1-RING-domain, 4 mM ATP, 4 mM MgCl2, 0.5 mM DTT and 
50 mM Tris/HCl pH 7.5. 
Single turnover in vitro ubiquitination reactions contained 1 µM fluorescently labelled 
(Alexa488) monoubiquitin (Ub-S20C), 10 µM different C-terminally 6xHis-tagged acceptor 
Ub variants as indicated, 0.2 µM hUbe1 and 2 µM Ubc1. Alternatively, E2 variants were 
included as indicated. For single turnover ubiquitination reactions with Ubc7-U7BR in presence 
of ubiquitin binding domains (UBDs), the indicated UBDs were included in the reaction mix at 
at concentration of 40 µM in reactions with 48x3Ub4 and at a concentration of 20 µM with 48Ub2. 
For kinetic analyses reactions were performed in triplicate. Line plots for all lanes in any scan 
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were extracted using ImageJ. Data was then analysed by using the Multipeak Fitting Package 
in Igor Pro. Peaks were approximated with Gaussian functions and linear or constant baselines 
were automatically determined. Product intensity over total intensity per lane was plotted over 
time and approximated with a line function. Initial reaction rates were determined as slope of 
the function. 
In vitro ubiquitination reactions in section 2.2.3.2 (for de novo chain synthesis) contained 
12 µM fluorescently labelled (Alexa488) monoubiquitin, 3 µM 63x3Ub1(G76-6xHis) where 
indicated, 2 µM Ubc1 or variants, 4 mM ATP, 4 mM MgCl2, 0.5 µM DTT, and 50 mM Tris/HCl 
pH7.5. 
Preparative autoubiquitination of Ubc1 for structural analysis was performed with 
0.5 µM E1 hUbe1, 100 mM Ubc1, 110 mM Smt3-A-hUb(K48R), 4 mM ATP, 5 mM MgCl2, 
0.5 µM β-ME, 50 mM NaCl and 50 mM Bis-Tris propane pH9.5. The reaction mix was 
incubated for one hour at 4°C. 
4.2.2.9 Fluorescent labelling of Ub 
Ub(S20C) or Ub with a c-terminal 6xHis-tag and cysteine were fluorescently labelled using 
Alexa Fluor 488 C5 Maleimide (Life Technologies). Thiole groups were reduced with two-fold 
molar excess of TCEP in 1x PBS for 10 min at RT. The sample was desalted using NAP5 
columns and incubated with the fluorescent dye in 1x PBS for 90 min in the dark. Subsequently, 
the sample was desalted twice using NAP5 columns equilibrated in 50 mM Tris/HCl ph 8. The 
sample was concentrated in an Amicon Ultra concentrator (3K MWCO, Millipore). Final 
protein concentration was determined by a Lowry test. Labelling efficiency was assessed by 
absorbance measurement at 488 nm. 
4.2.2.10 In vitro ubiquitin binding assay 
To investigate binding properties towards differently linked Ub chains, freshly prepared GST-
tagged proteins immobilised on GSH-resin were used after the wash step of the purification 
protocol and equilibrated to Ub binding buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1g/l 
BSA). Amounts of different constructs were adjusted and evaluated by SDS-PAGE and 
subsequent Coomassie staining. Differently linked Ub chain mixes were diluted to a final 
concentration of 25 µM monoubiquitin equivalent in Ub binding buffer. 25 µl GSH-resin with 
immobilised GST-proteins were then incubated with 150 µl of the respective chain mix for 2h 
at 4°C on a rotating wheel. After the binding step the samples were centrifuged at 800 x g for 
1 min and the supernatant was removed. The resin was then washed two times in Ub binding 
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buffer. Urea sample buffer was added to the supernatant and washed resin and heated to 35°C 
for 5 min. Samples were then analysed by SDS-PAGE, fluorescence scan and Coomassie 
staining. 
4.2.2.11 Chemical cross-linking with ethane-dithiol (EDT) 
All steps of protein cross-linking were performed in cross-linking buffer (20 mM HEPES 
pH7.0, 250 mM NaCl, 5 mM EDTA). Proteins destined for cross-linking were transferred to 
cross-linking buffer containing 0.5 mM TCEP by SEC during the preceding purification step. 
Immediately before the procedure, stock solutions of 256 mM 2,2-Dithiodipyridine (AT2) in 
DMSO and 256 mM 1,2-ethanedithiol (EDT) in DMSO were freshly prepared. Moreover, 
5 Zeba Spin Desalting Columns (ThermoFisher) were equilibrated to cross-linking buffer to 
perform buffer exchange steps. All steps were performed at RT and solutions prewarmed if 
necessary. 132 mg 63Ub2 in 3.65 ml buffer (2.13 mM) were buffer exchanged to cross-linking 
buffer, added to 100 µl AT2-stock solution and immediately mixed by pipetting up and down. 
After 10 min incubation, the sample was buffer exchanged and mixed with 100 µl EDT stock 
solution by pipetting up and down. After 5 min incubation, the sample was buffer exchanged 
and mixed with 100 µl AT2-stock solution by pipetting up and down. After 10 min incubation, 
the sample was buffer exchanged. In parallel, 130 mg Ubc1-Ub in 3.92 ml buffer (1.05 mM) 
was also buffer exchanged and subsequently mixed with the 63Ub2 solution. After 90 min 
incubation the sample was concentrated to 3 ml and 500 µl aliquots were loaded on 6 separate 
HiLoad 16/600 Superdex 75 pg columns for SEC (0.5 ml/min, 20 mM Tris/HCl pH8, 200 mM 
NaCl). Fractions most concentrated for the cross-linked complex were united, concentrated to 
14.6 mg/ml using Amicon Ultra centrifugal filters (Millipore), aliquoted, snap frozen and stored 
at -80°C. Side fractions from the SEC run, which contained impurities, were concentrated and 
prepared for another SEC run. 
4.2.3 Biophysical Methods 
4.2.3.1 Microscale thermophoresis (MST) 
To assess binding affinity between Ubc1 differently linked diubiquitin molecules microscale 
thermophoresis was performed. Experiments were performed with the NanoTemper Monolith 
NT115. Method development and measurements were designed according to manufacturer’s 
guidelines. Different conditions for monitoring thermophoresis of the diubiquitin probes were 
tested, but only one condition was identified to satisfy the quality parameters outlined by the 
manufacturer: 200nM Ub2*, 50 mM MES pH 6.2, 200 mM NaCl with coated tubes and 
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capillaries. Excitation Power was set to 20% and MST power to 60%. The thermophoretic 
mobility of diubiquitin probes was measured in presence of different concentrations of Ubc1 
(3.2 mM to 0.4 µM). Measurements were performed in triplicate. Experiments were designed 
and carried out under the supervision of Dr. Stefan Übel (Biophysical core facility, MPIB, 
Martinsried). 
4.2.3.2 NMR titration experiments 
NMR titration experiments enable identification of surface residues involved in binding166 as 
well as determination of dissociation constants167. NMR spectra were acquired on Bruker 
Avance spectrometers operating at proton frequencies ranging from 500 MHz to 950 MHz 
equipped with 5-mm triple-resonance cryogenic z-axis gradient probes. Samples were 
measured in salt tolerant NMR tubes in a total volume of 300-400 µl. Chemical shift referencing 
was performed with 4,4-dimethyl-4-silapentane-1-sulphonate (DSS). Spectra were processed 
using the TopSpin software provided by Bruker and analysed using SPARKY 3.13 software or 
NMRFAM-SPARKY.168 NMR titration experiments with UBDs were performed with either 
Cue1 (aa45-115) or Ubc1 (aa151-215) in concentrations ranging from 0 to 1.6 mM and 
diubiquitin probes at a concentration of 0.2 mM at 298K. Diubiquitin probes were either 
proximally or distally 15N-labelled 48Ub2 or 63Ub2. Dr. Andreas Kniss from the laboratory of 
Prof. Dr. Volker Dötsch performed all NMR measurements presented in this study. 
4.2.4 Cell biology 
4.2.4.1 Yeast cultivation 
The cell density of liquid cultures was typically determined by measuring the optical density in 
a spectral photometer at a wavelength of λ = 600 nm (OD600). 
For SILAC labelling cells were grown in SD medium containing 30 mg/l Lys4. 
4.2.4.2 Heat-shock transformation of yeast cells 
Yeast strains were grown in logarithmic growth phase (OD600 < 1/ml) and an amount of cells 
equivalent to 1 ml culture at 1 OD600/ml (“1 OD600”) were harvested by centrifugation at 
3000 x g for three minutes. The pellet was first washed with water and then with a solution of 
100 mM LiOAc, 10 mM Tris/HCl pH 7.4 and 10 mM EDTA. 200 µl of this buffer were prepared 
and incubated with 3 µg of the desired DNA and 0.2 µg/µl of denatured Hering sperm DNA for 
several minutes. After the wash steps the cell pellet was resuspended in this solution and 800 µl 
of 40% PEG 335, 100 mM LiOAc, 10 mM Tris/HCl pH 7.4 and 10 mM EDTA was added. The 
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suspension was incubated for 30 minutes at 30°C and subsequently heat shock was performed 
for 15 minutes at 42°C. Cells were spun down at 3000 x g for 1 minute, resuspended in 100 µl 
water and plated onto selective SD plates. Plates were incubated for 1-3 days at 30°C and then 
stored at 4°C for no longer than one week. 
4.2.4.3 Preparation of genomic DNA from yeast cells 
Genomic DNA was prepared from yeast cells as template for PCR reactions. Cells were grown 
over night in YPD medium cells equivalent to 4-10 OD600 were harvested by centrifugation 
(2000 x g, 5 min at RT). Cells were washed with 1 ml ddH2O, centrifuged as before and 
resuspended in 200 µl DNA extraction buffer (2% Triton X-100, 100 mM NaCl, 1% SDS, 
1 mM EDTA and 10 mM Tris/HCl pH 8.0). Subsequently, 200 µl of a mixture of phenol, 
chloroform and isoamyl alcohol (25:24:1) was added and mechanical cell lysis was performed. 
Lysate was transferred to fresh tube with 200 µl TE buffer (pH 8) and centrifuged for 10 min at 
10000 x g at RT. The samples separated into two phases. The aqueous (upper) phase was 
removed and added to 1 ml of pure ethanol in order to precipitate DNA on ice by centrifugation 
(20000 x g for 10 min at 4°C). The supernatant was discarded and the precipitated DNA was 
resuspended in 100 µl ddH2O. 
4.2.4.4 Mechanical lysis of yeast cells 
Total yeast cell extract was prepared for SDS-PAGE and western blotting as well as for 
analytical PCRs. Typically cells were grown to 1.0 OD600/ml and 5-20 ml were harvested by 
centrifugation at 2000 x g for 3 min at RT. The cell pellet was resuspended in 100 µl lysis buffer 
(50 mM Tric/HCl, 1% SDS, 1 mM PMSF) and transferred to a 2 ml eppendorf tube. Glass 
beads were added up to the meniscus of the liquid and the suspension was vortexed for 2 min 
at maximum speed in a Vibrax VXR basic. For direct analysis by SDS-PAGE and western 
blotting, the lysate was mixed with SDS sample buffer, boiled for 5 min at 95°C, centrifuged 
for 3 min at 1000 x g and the supernatant loaded onto a gel. Alternatively, dilution buffer was 
added to the lysate for further processing where indicated. 
4.2.4.5 Cycloheximide chase assay 
Cycloheximide chase experiments were performed with 20 OD600 log-phase cells, which were 
harvested and resuspended in 4.5 ml prewarmed SD medium containing 100 mg/ml 
cycloheximide. Cell suspensions were incubated at 30°C in a water bath. 1 ml aliquots were 
taken in 30 min intervals. Degradation was stopped by the addition of 15 mM NaN3, and total 
cell lysates were prepared. Samples were analysed by SDS-PAGE and immunoblotting. 
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4.2.4.6 Detection of Ub linkage types on Htt in S. Cerevisiae by mass spectrometry 
The respective yeast strains were grown over night in SD medium –LYS and diluted to 
0.3 OD600/ml in 400 ml the next morning. After growth until 0.9 OD600/ml at 30°C, 
1 mM CuSO4 was added and cells were grown for approximately another 1.5h to 1 OD600/ml. 
Cells were harvested by centrifugation at 3000 x g for 5 minutes, washed twice with ddH2O and 
resuspended in 50 ml YP GAL with 0.2 mM CuSO4. Another incubation step was performed 
for 1h at 30°C. As before cells were harvested by centrigution, washed with ddH2O and the 
pellet flash frozen in liquid nitrogen. Pellet was stored at -80°C. Thawing on ice for 30 min was 
followed by resuspension in 1 ml lysis buffer (8 M Urea, 50 mM HEPES pH7.6, 5 mM 
chloroacetamide) in a 15 ml Falcon tube. Glass beads were added to a total volume of ~3.5 ml 
for mechanical lysis at maximal speed for 5 minutes by Vibrax VXR basic. Subsequently 8 ml 
dilution buffer (50 mM HEPES pH7.6) were added, followed by centrifugation for 5 min at 
800 x g after inverting the tube several times. Supernatant was transferred to a fresh 15 ml 
Falcon tube and 40 µl M2 FLAG-affinity gel (Sigma A2220) was added, which was previously 
washed with dilution buffer. After incubation for 3h at 4°C on a rolling incubator, resin was 
centrifuged and washed three times with 1 ml dilution buffer. Supernatant was completely 
removed with a Hamilton pipette. 50 µl elution buffer (8 M Urea, 50 mM HEPES pH7.6) was 
added and incubated at 30°C for 1h in a heating block. The eluate was transferred to a fresh 
tube using a Hamilton pipette and protein amount adjusted as assessed by BCA assay. Samples 
were flash frozen and stored at -20°C until further processing. Subsequent steps were performed 
by Dr. Oliver Popp from the mass spectrometric core facility under the supervision of 
Dr. Philipp Mertins (MDC, Berlin). 
After thawing, the eluate was subjected to reduction, alkylation and in-solution digest with 
50 ng LysC and 50 ng trypsin in a consecutive manner. After desalting, half of the samples have 
been acquired in a data-dependent mode by LC-MS on a Q Exactive Plus mass spectrometer 
using a 2 h gradient. The other half was spiked with 200 fmol heavy labelled internal standard 
peptide of the respective ubiquitin linkage type marker peptides (SpikeTides TQL, JPT) as an 
internal reference and subjected to parallel reaction monitoring (PRM) analysis on a Q Exactive 
Plus mass spectrometer. Data obtained from the discovery-experiment was analysed using the 
MaxQuant software package169 version 1.5.2.8., PRM data was analysed using Skyline170. Data 
visualisation was achieved using R. 
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4.2.4.7 Sample preparation for mass spectrometric detection of K48/K63 branched 
chains from yeast lysate 
To investigate the abundance of K48/K63 branched chains in dependence of Ubc1 expression 
in S. cerevisiae, yeasts strains expressing 10xHis-Ub(R54A) and no other Ub gene were grown 
in either unlabelled or Lys4-labelled media. Precultures were diluted to 0.03 OD600/ml and then 
grown to 1.1 OD600/ml. To compare two conditions, equal amounts (400 ml) of cells grown in 
unlabelled media from one strain were combined with cell grown in Lys4-labelled media from 
the other strain and reverse. The combined cells were centrifuged for 10 min at 2000 x g, 
resuspended in 3 ml lysis buffer (8 M urea, 1% SDS, 50 mM HEPES pH 8.0, 1 mM PMSF), 
transferred to a 15 ml Falcon tube, flash frozen in liquid nitrogen and stored at -80°C overnight. 
Pellets were thawed on ice and 3 ml glass beads were added for subsequent mechanical lysis at 
RT by Vibrax VXR basic at maximum speed for 3 min. After lysis, 6 ml equilibration buffer 
were added (EB, 8 M Urea, 50 mM HEPES pH 8.0), inverted several times and centrifuged at 
5000 x g for 5 min at RT. Supernatant was removed and centrifuged again at 20000 x g for 
20 min at RT. Subsequent steps were carried out with LC-MS grade reagents and under the 
fume hood. Per sample 150 µl Talon-resin was washed in EB, added to the cleared supernatant 
and incubated for 3h at 4°C on a rotating wheel. Resin was removed from the solution by 
centrifugation for 1 min at 800 x g, washed six times with EB and one time in 150 µl 
denaturation buffer (DB, 6 M urea, 2 M thiourea, 10 mM HEPES pH 8.0). Resin was then 
resuspended in 50 µl DB, reduced with 0.8 mM DTT for 30 min at RT and alkylated with 1 mM 
2-Chloroacetamide for 20 min at RT in darkness. Samples were kept in darkness from here on. 
Then, 3 µg LysC protease were added and incubated for 3h at RT under shaking. 200 µl 50 mM 
ammonium bicarbonate buffer were added to dilute the sample, before adding 3 µg trypsin for 
digest at RT overnight. After a final centrifugation at 800 x g for 1 min the supernatant was 
removed and acidified with 25 µl 10% trifluoroacetic acid. Samples were then given to Dr. 
Henrik Zauber from the laboratory of Prof. Matthias Selbach for analysis by Parallel Reaction 
Monitoring (PRM). 
4.2.4.8 Mass spectrometric analysis of K48/K63 branched chains 
A spectral library for K48/K63 branched chains was obtained from a Ub trimer, which was 
prepared as outlined in section 2.2.4.1. The Ub trimer was incubated with trypsin in a mass ratio 
of 50:1 and incubated over night at RT. Tryptic peptides were separated by reverse phase 
chromatography (200 min gradient) and analysed by mass spectrometry on a Q-Exactive Plus 
(Thermo Fisher Scientific). Settings in brief were: 70000 MS1 resolution, 120 ms MS1 MaxIT, 
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300-1700 m/z scan range, 17500 MS2 resolution, 2.0 Da isolation window, 26 normalised 
collision energy, MS2 AGC target 5e2, 60 ms MS2 MaxIT. 
Samples obtained from yeast lysate as described in the previous section were subjected to 
LC-MS/MS analysis. To this end, peptides were separated by reverse phase chromatography on 
a 130 min gradient, with increasing concentrations of Buffer B (80 % acetonitrile, 0.1 % formic 
acid) from 2 to 90 % and analysed on a Q-Exactive Plus (Thermo Fisher Scientific). The PRM 
settings were: 35000 resolution, 2e5 AGC target, 2 m/z isolation window, 120 ms max ion 
injection time. Precursors have been selected based on a report from Ohtake et al.58 The DDA 
(top3) settings were: 17500 MS1 resolution, 60 ms MaxIT, 17500 MS2 resolution, 60 ms 
MaxIT, 2 Da isolation window. 
PRM data was analysed using the open source Skyline analysis tool.170 Peaks were manually 
assigned and validated based on the DotProduct. Exported fragment intensities were analysed 
using R. To identify other peptides from the top3 acquisition part of the data, raw-files were 
analysed with MaxQuant (1.5.2.8) with standard settings and setting complexity to 2 for 
analysis of SILAC ratios. Shifts in the log2 ratio distribution were used to correct the log2 ratios 
of corresponding fragments from the PRM analysis and plotted against the fragment intensities. 
4.2.5 Crystallography 
4.2.5.1 Crystallisation conditions and data collection 
Initial protein crystallisation trials were performed in a 96-well sitting drop format at 4°C. 
Commercial screening kits (Hampton Research Index, Molecular Dimensions JCSG-plus, 
Qiagen pHClear 2) and “Complex 1” screen (made by the crystallisation core facility at MPIB, 
Martinsried) were used in. Per well 0.1 µl protein solution (15 mg/ml) was dispensed in 0.1 μl 
reservoir solution using a nanoliter crystallisation robot (Phoenix). During initial screenings, 
the complex formed protein crystals in form of needle-stacks within a week in 15% PEG 6000, 
0.1 M magnesium acetate and 0.1 M sodium cacodylate (pH 6.5) as well as in 8% PEG 6000, 
0.1 M magnesium chloride and 0.1 M MES (pH 6.0). Crystallisation conditions were optimised 
by Dr. Jérôme Basquin in 24 well format using sitting drops with 0.4 µl protein solution and 
0.4 µl reservoir solution. Optimisation was achieved by microseeding in combination with 
variation of precipitant and salt concentrations as well as pH. The final crystallisation conditions 
were 10°C in 6.5% PEG 6000, 100 mM MgCl2, 100 mM HEPES pH 7.0. The protein complex 
crystallised as needles. A diffraction dataset was recorded by Dr. Basquin at PXII beam line, 
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Swiss Light Source (SLS) Villingen, Switzerland. Data was recorded at 0.5 degree rotation 
intervals using PILATUS detector. 
4.2.5.2 Phasing and model building 
Data was indexed, integrated and scaled using XDS package171 to a resolution limit of 3.2 Å. 
Initial analysis revealed two molecules per asymmetric unit with a matthews coefficient of 1.96 
and 37% solvent content. Phases were determined by Dr. Rajan Prabu (MPIB, Martinsried) 
using molecular replacement based on previously published PDB structures using PHASER 
software implemented in the PHENIX software suite.172 I improved the model by interactive 
model building using coot173 and reciprocal space refinement using phenix.refine172. We used a 
twin law (h, -k, -l ) during refinement to compensate for the lattice twinning. 5% of reflections 
were kept aside to evaluate the model. The final refined structure had an R-factor of 20.2 % and 
Rfree of 23.2 %. For final data collection and refinement statistics, which were obtained using 
MolProbity174, refer to Table 1 (page 91). Molecular graphics and analyses were performed 
with UCSF Chimera.175 
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5. Supplementary data 
5.1 Summary of data collection and refinement statistics 
Table 1 Summary of data collection and refinement statistics. 
Ubc1 
 
Resolution range (Å) 76.77 - 3.11 (3.22 - 3.11)* 
Space group C 1 2 1 
Unit cell dimensions  
        a, b, c (Å) 57.85, 132.69, 153.55  
        α, β, ɣ (°) 90, 90.12, 90 
Total reflections 42476 (13928) 
Unique reflections 20859 (589) 
Multiplicity  6.8 (6.6) 
Completeness (%) 84.46 (27.86) 
Mean I/sigma(I) 8.89 (0.95) 
Wilson B-factor 80.1 
R-merge 0.201 (2.132) 
R-meas 0.2179 (2.317) 
R-pim 0.08314 (0.8966) 
CC1/2 0.995 (0.543) 
CC* 0.999 (0.839) 
Reflections used in refinement 17701 (589) 
Reflections used for R-free 870 (21) 
R-work 0.2023 (0.5420) 
R-free 0.2322 (0.7652) 
CC(work) 0.878 (0.456) 
CC(free) 0.821 (0.104) 
Number of non-hydrogen atoms 5223 
RMS(bonds) (Å) 0.006 
RMS(angles) (°) 1.14 
Ramachandran favored (%) 98.13 
Ramachandran allowed (%) 1.87 
Ramachandran outliers (%) 0 
Rotamer outliers (%) 0 
Clashscore 11.67 
Average B-factor 63.73 
   *Values in parenthesis are for highest resolution shell. 
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5.2 Electron density map of the crystallised Ubc1 complex 
 
Figure 30: Representative images for the electron density map obtained for Ubc1-Ub-X-63Ub2.  The 2Fo − Fc 
electron density map (grey mesh) was contoured at 1.1σ (grey mesh). (A) Critical residues in the interface between 
UBA domain and Ub are shown as sticks. (B) Interface between UBC domain and UbA in stick representation. 
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5.3 Supplementary fluorescence scans for section 2.2.3.2 
 
Figure 31: Representative fluorescence scans of single turnover ubiquitination experiments for kinetic 
analysis described in section 2.2.3.2. Top row shows reactions with the UBC domain of Ubc1(K93R), while the 
other reactions were performed in presence of full-length Ubc1 (K93R). Acceptor Ub as in Figure 20. Asterisk (*) 
indicates signal from free dye. Cross (†) indicates E1 modified with fluorescent Ub. 
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